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ABSTRACT 
Alan C. Kinlaw: Antibiotic Prescribing during Infancy and Risk of Treated Obstructive Airway 
Diseases during Early Childhood: A Registry-Based Nationwide Cohort Study in Denmark 
(Under the direction of Til Stürmer) 
 
Widespread antibiotic use leads to bacterial resistance, and antibiotic use in early life may 
be associated with asthma in childhood. To date, studies of this association have led to 
inconsistent findings. Additionally, data are limited regarding cohort effects on antibiotic use in 
children, which may impact underlying susceptibility to adverse effects. 
Using nationwide registry data on all children born in Denmark during 2004-2012, our 
objectives were to (1) examine birth-season and birth-year cohort effects on antibiotic 
prescribing during the first year of life (henceforth, ‘infancy’), and (2) to estimate 1-, 2-, and 3-
year risk differences (RD) for the association between antibiotic prescribing during infancy and 
treated airway diseases from 2-5 years of age, using propensity scores (PS) and instrumental 
variables. 
The 1-year risk of redeeming at least one antibiotic prescription during infancy was 39.5 
per 100 children. The hazard of first redeemed antibiotic prescription increased with age 
throughout infancy, and peaked in February; as a result, season of birth impacted overall 1-year 
risk of redeeming an antibiotic prescription during infancy and age at first redeemed antibiotic 
prescription. Amoxicillin prescribing was dynamic over the study period, but decreased after 
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distribution of a bulletin on rational antibiotic use in general practice and rollout of two 
nationwide pneumococcal vaccination programs. 
In PS analyses, antibiotic exposure was associated with increased risk of treated airway 
diseases by age 5, compared with no exposure (3-year RD = 4.5 per 100 children, 99% 
confidence interval (CI): 4.2, 4.8). PS-based dose-response analysis suggested that each 
additional redeemed antibiotic prescription was associated with increased risk of 2.4 per 100 
children (99% CI: 2.3, 2.5). RDs were negligible in a PS-based head-to-head comparison 
between two antibiotics with similar indications but differing spectrum of antibacterial activity – 
amoxicillin and penicillin V (3-year RD = -0.1 per 100 children, 99% CI: -0.6, 0.3). Results from 
instrumental variable analyses also cast some doubt on the presence of a causal effect, but were 
imprecise. These results suggest that antibiotic exposure during infancy may increase the risk of 
treated airway diseases, but further exploration is needed using data and methods capable of 
addressing potential residual confounding. 
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CHAPTER 1: STATEMENT OF SPECIFIC AIMS 
 
 
Asthma is one of the most common chronic diseases in childhood, and poses a significant 
worldwide burden.
1–3
 Childhood asthma prevalence ranges 3-7% in Denmark,
4,5
 and 
approximately 10% of children take prescription medication to treat related symptoms.
6,7
 The 
prevalence of asthma, atopic response, and other allergic conditions has increased in recent 
decades,
1,2,8–12
 especially in industrialized areas,
3,13,14
 but reasons for these increases are 
unclear.
1,2,15–19
   
Many causes have been hypothesized to explain observed increases in asthma 
prevalence.
13,14
 Along with genetics,
20,21
 environmental factors,
20–24
 and viral infection,
20,21,24
 the 
“hygiene hypothesis”25  may also explain recent increases in the prevalence of childhood asthma, 
especially in industrialized countries.
14
 This controversial
19
 hypothesis asserts that adequate 
microbial exposure is important for developing proper immune response in early life.
19,26
 
Subsequently, child development in an overly hygienic environment – with lower exposure to 
microbiota – may induce elevated atopic response in children and elevated risk of the 
development of asthma.
7,14,27–29
  
 Given that antibiotics deplete and disrupt bacterial flora in the gut,
30,31
 they have long 
been suspected to cause increased risk of atopic immune response and asthma, particularly in 
children.
14,32
 Over the last two decades, numerous epidemiologic studies have examined the 
potential association between childhood antibiotic exposure and asthma,
12,14,26,33–37
 yielding 
2 
conflicting results.
13,38
 Each prior study has been limited by intractable biases, including 
confounding by indication or other unmeasured factors, reverse causality, other protopathic bias, 
and recall bias. 
Antibiotic prescribing is common in children,
32,39
 and unnecessary use frequently occurs 
because bacterial and viral variants of upper respiratory tract infections are often clinically 
indistinguishable.
40–43
 Decreasing unnecessary antibiotic prescribing is a critical feature of 
clinical and public health approaches to stifle mounting threats of population-level bacterial 
resistance.
32,40,44–47
 In western industrialized countries in particular, increasing advocacy for 
rational antibiotic prescribing has been associated with decreases in population-level antibiotic 
use.
48–51
 In addition, pneumococcal conjugate vaccination programs have been associated with 
decreased risk of acute otitis media and lower respiratory tract infections,
52
 two of the most 
common indications for antibiotics in children.  
The overall goals of this research are to characterize the changing patterns of antibiotic 
prescribing in children to inform future studies of antibiotic effectiveness and safety, and to 
examine the relation between early life antibiotic prescribing and the development of obstructive 
airway diseases in childhood. This dissertation has two primary aims:  
 
1.1. SPECIFIC AIM 1 
 Describe antibiotic prescribing patterns during the first year of life among children born 
in Denmark during 2004-2012, with attention to birth-month, birth-season, and birth-year cohort 
effects. Additionally, part of this investigation addresses the potential impact of two population-
level changes during this time period:  
3 
(1)  a nationwide bulletin issued from the Danish Health and Medicine Authority’s Institute 
for Rational Pharmacotherapy (IRF) to general practitioners in April 2007 with 
guidelines for rational antibiotic prescribing,
47
 and  
(2)  the Danish childhood vaccination program’s rollout of the 7-valent pneumococcal 
conjugate vaccine (PCV7) in October 2007 and the 13-valent vaccine (PCV13) in April 
2010.
53–55
  
 
1.2. SPECIFIC AIM 2 
 Assess the association between antibiotic prescribing during the first year of life and 
incidence of treated obstructive airway diseases during early childhood, among children born in 
Denmark during 2004-2012. Based in part on evidence from Aim 1, this investigation focuses on 
estimating risk differences for the effect using propensity scores
56,57
 and instrumental variables
58–
60
 to address bias, including assessment of a dose-response relation and heterogeneity of effects 
by age at first exposure to antibiotics. The individual-level analysis in sub-aim 2a reduces 
potential confounding to estimate associations between antibiotic prescribing and treated airway 
diseases in childhood; the ecologic analysis in sub-aim 2b uses instrumental variables under the 
potential outcomes methodological framework
58
 intended to assess explicit causal associations 
between antibiotic prescribing and treated airway diseases.   
 
Sub-aim 2a 
 Conduct an individual-level analysis of the relation between exposure to antibiotics 
during the first year of life and incident treated airway diseases in early childhood. Using linked 
registry data with rich covariate information on family medical history, pregnancy, infant health, 
4 
hospital and clinic visits, prescriptions and demographics, this assessment relies on propensity 
score-based
56,61–63
 weighting methods
64,65
 to reduce confounding and to estimate population-level 
measures of absolute risk of treated airway diseases across levels of antibiotic exposure, 
including head-to-head comparisons between amoxicillin and penicillin V, dose-response 
analysis, and an assessment of risk difference heterogeneity by age at first exposure.  
 
Sub-aim 2b 
Conduct time-based ecologic analyses related to population-level occurrence of antibiotic 
prescribing and treated airway disease. Using birth-season cohort and calendar time as 
instrumental variables,
58–60,66,67
 this analysis estimates effect estimates analogous to a 
randomized controlled trial with non-compliance. Instrumental variable analysis is conditional 
on three assumptions, which in the context of this study are as follows: (1) the instrument affects 
the proportion of children exposed to antibiotics; (2) the instrument is unrelated to other 
covariates such that the association between the instrument and risk of treated airway diseases is 
not confounded; and (3) the instrument does not directly affect the risk of treated airway 
diseases. Together, these assumptions imply that the instrument can only be associated with the 
risk of treated airway diseases if antibiotic exposure has an effect on treated airway 
diseases.
58,60,68
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1.  BACKGROUND 
Asthma is a major chronic disease worldwide and its prevalence is increasing. 
Asthma is one of the most common chronic conditions among children 
worldwide.
1,3,20,69,70
 Asthma-related mortality among children is relatively low compared with 
other health conditions,
71
 but it impacts overall health and quality of life.
1
 Especially when 
compared to other illnesses that may be non-fatal,
72
 asthma imposes one of the heaviest burdens 
of disease in the world today.
1,70,72,73
 Prevalence of childhood asthma ranges from 2-11% across 
world regions,
3,74,75
 and from 3-7% in Denmark.
4,5
 In Denmark, risk of asthma has been 
estimated at 10%
76
 and 6%
77
 by 7 years of age; 14%
78
 and 5%
79
 by 10 years of age; and 5%
80
 by 
12 years of age.  
The prevalence of asthma, atopic response, and other allergic conditions has increased in 
recent decades,
1,2,8–12,14
 especially in industrialized areas,
3,13,14
 and asthma is now the most 
common chronic condition among children worldwide.
69
 Based on preliminary data,
81
 
approximately 5-10% of children in Denmark aged 5-14 years were prescribed medication for 
treatment of obstructive airway diseases between 2000 and 2013. These observations are similar 
to those in the United States, where approximately 10% of children and 5% of adults were 
prescribed medication for treatment of asthma in 2006.
3,7,14,82
 
6 
Despite recognition of population-level increases in asthma, reasons for these increases 
are unclear.
1,2,15–19
 Many causes have been hypothesized to explain observed increases in asthma 
prevalence;
13,14
 however, as the underlying causal framework of asthma morbidity remains 
unestablished,
20,21
 so does our understanding of changes in its prevalence. Asthma is an 
inheritable condition, but relationships between genetic factors and asthma phenotypes are not 
clearly defined and are not sufficient to explain increases in occurrence of asthma.
20,21
 Increasing 
childhood asthma prevalence may also be caused by changing environmental factors such as 
increased airborne allergen levels (e.g., house dust mites and Alternaria fungi);
20,22,23
 respiratory 
infection by rhinovirus (RV) and respiratory syncytial virus (RSV);
20,21
 and increased 
urbanization, air pollution, chemical irritants, and tobacco smoke.
7,13,14,20,21,26,69
  
  
The “hygiene hypothesis” is a biologically plausible explanation of increasing asthma. 
In addition to those potential causes mentioned above, the “hygiene hypothesis”25  may 
also explain recent increases in the prevalence of childhood asthma, especially in industrialized 
countries.
14
 This controversial
19
 hypothesis asserts that adequate microbial exposure is important 
for developing proper immune response in early life.
19,26
 This hypothesis originated from 
observations of individuals with high exposure to microbiota with less incident respiratory 
problems than those with lower exposure levels,
25
 and has been extended to offer an explanation 
for observed increases in asthma and atopy among individuals with low exposure to microbiota. 
Subsequently, child development in an overly hygienic environment – with lower exposure to 
microbiota – may induce elevated atopic response in children and elevated risk of the 
development of asthma.
7,14,27–29
  
7 
In infants and adults, bacterial flora in the gut is impacted by host genetics and can be 
depleted by infection, chemotherapy and radiation; depletion is also thought to occur following 
exposure to antibiotics and might explain the onset of suboptimal immune function following 
anti-infective treatment.
30,83
 Factors in early life which are suspected to increase the child’s 
microbial exposure include vaginal delivery (versus cesarean), later gestational age at birth, 
breastfeeding during infancy, as well as bacterial characteristics, human mucosal cell 
characteristics, and child antibiotic use.
13,24,84–86
 Experiments in mice have also demonstrated 
that microbial exposure in utero protects against allergic phenotypes and that sufficient bacterial 
gut colonization in early life plays an important role in immune response programming.
14,87–90
 
Observational studies in children have also suggested that prenatal antibiotic exposure may also 
increase risk of asthma;
91–94
 however, it is important to note that potential associations between 
antibiotic exposure and asthma in the prenatal and postnatal period are likely based on distinct 
biologic mechanisms, given that the human fetal gut is thought to remain sterile in utero.
95
 
Proper immune response is generally characterized as a balance between T-helper type 1 
(Th1) and T-helper type 2 (Th2)
96,97
 cytokine responses.
20
 Th1 cytokine (e.g., interferon-γ) 
responses are largely for proinflammatory killing of intracellular organisms, whereas Th2 
responses promote immunoglobulin E (IgE) antibodies to combat multicellular helminths, and 
are more anti-inflammatory.
19,21,97
 A Th1-skewed response profile could result in tissue damage, 
and a Th2 skew could result in asthma and other atopic phenotypes.
97
 These potential 
abnormalities underscore the need for adequate balance of the Th1/Th2 mechanisms for proper 
immune response.
20,21,97
    
The natural history of the early life Th1/Th2 balance is essential to the proposed study of 
antibiotic exposure during infancy and childhood asthma, because this balance impacts infant 
8 
susceptibility and response to infection. During pregnancy, the balance is Th2-skewed because 
the fetal environment is largely sterile
95
 and autoimmune response could lead to preeclampsia or 
spontaneous abortion.
21
 After experiencing its first major contact with microflora by traveling 
through the birth canal, the healthy infant’s naïve, Th2-skewed and hyporesponsive immune 
system adapts slowly over the course of childhood to a more balanced and robust state.
21,98
 
However, insults to the naïve infant immune system – by such means as repeated viral infection 
or antibiotic exposure – may lead to immune dysfunction in later childhood years.98   
       
Antibiotic prescribing to children often occurs for viral infections and may often be unnecessary. 
  Out of all antibiotic prescriptions to children, nearly one-third occur for non-bacterial 
upper respiratory tract infections
14,26,28,29,32,99
 for which they are not effective.
32,100
 Although 
there is some interest in macrolide antibiotics – Anatomic Therapeutic Chemical (ATC) group 
J01FA
101
 – as potentially beneficial in treatment of infection due to their anti-inflammatory 
properties, there is otherwise very little evidence for benefit to children prescribed antibiotics for 
viral infection.
21,100
 
Most acute upper respiratory tract infections (e.g., bronchitis, sinusitis, pharyngitis) are 
viral and self-limiting.
32,40,102
 In a small proportion of children, these viral infections can be 
accompanied or followed by secondary bacterial infection(s), including acute otitis media, 
sinusitis, and pharyngitis.
32,40,102
 The common pathogens that cause acute otitis media and 
sinusitis are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis,
45,103
 
whereas Streptococcus pyogenes and Mycoplasma pneumoniae are the primary bacterial causes 
of pharyngitis.
104
 Antibiotics are prescribed to children for treatment of upper respiratory tract 
infections because (a) bacterial and viral infections are often clinically indistinguishable among 
9 
children with variable levels of atopic response,
40,41
 and (b) antibiotics are protective against 
secondary suppurative complications from bacterial infection.
32,40,102
 In settings with low access 
to healthcare, prophylactic antibiotic prescribing may be more sensible than in settings with high 
access to healthcare, where watchful waiting
45
 can be used and children who show symptoms of 
bacterial infection at a proximate follow-up visit can subsequently be prescribed an antibiotic. 
These complications (e.g., mastoiditis, pneumonia, peritonsillar abscess) are serious 
outcomes, but rare among children with upper respiratory tract infection, on the order of 
<0.1%.
32
 
32,45,105,106
 For example, although antibiotics are effective for preventing mastoiditis, the 
incidence of mastoiditis is extremely low regardless of antibiotic treatment; in order to prevent 
one case of mastoiditis among children, two studies have estimated that >4,800
106
 and >12,000
107
 
cases of otitis media would require antibiotic treatment. Such a high magnitude for the number 
needed to treat (NNT) estimand may elucidate some of the complexity surrounding opinions on 
antibiotic prescription recommendations. 
 
Antibiotic exposure in infancy and early childhood is modifiable. 
In the United States pediatric population in 1992, approximately 40% of doctor visits for 
viral infections resulted in an antibiotic prescription.
99
 In Europe, providers’ misconceptions of 
the risks and benefits pertaining to antibiotic prescription has been associated with increased 
prescribing.
42
 With such data in mind to inform both practitioners and parents, it is feasible that 
antibiotic prescriptions can be reduced at the population level and targeted more appropriately. 
As information has increasingly been disseminated over the last two decades about antibiotic 
effectiveness and bacterial resistance to subsequent antibiotic treatments,
32,40,44
 a burgeoning 
culture of increasingly judicious prescribing
51
 has resulted in decreases in antibiotic prescription, 
10 
especially in children.
48–50
 The continuing reduction of unnecessary and excessive prescription of 
antibiotics to infants and children is possible. Such a modification would curb the frequency and 
extent of microbial resistance to antibiotics,
32,40,48
 reduce incidence of other unintended adverse 
effects of antibiotics,
32,85
 and decrease unnecessary financial expenditures for antibiotics and 
further acute clinical consultation.
32
  
         
 
2.2. SOURCES OF BIAS IN STUDIES OF EARLY LIFE ANTIBIOTIC EXPOSURE AND 
CHILDHOOD ASTHMA 
The potential etiologic relation between infant antibiotic exposure and childhood asthma 
is difficult to assess due to uncertainty about the biologic mechanism and potential bias in 
epidemiologic studies. Asthma pathogenesis is highly complex,
20
 and investigators conducting 
observational studies have (justifiably) been criticized for narrowing their scope of inquiry 
toward straightforward explanations of potential risk factors for asthma.
19,34
 With respect to the 
‘hygiene hypothesis,’ in studies of antibiotic exposure and asthma, interpretation of results is 
usually carried out with implications toward acceptance or rejection of the ‘hypothesis,’ couched 
in language suggestive of causal structures, despite (always present and sometimes severe) 
limitations to inference. Furthermore, there are several biases that have likely impacted the 
results published so far on early antibiotic exposure and asthma. Each of these is described with 
a relevant example below. 
 
11 
Protopathic bias 
Protopathic bias,
7,14
 a type of reverse causality bias, can arise when underlying preclinical 
symptoms of the outcome of interest affect the treatment of interest. In a study of antibiotics and 
asthma, this could manifest if infants showing symptoms of underlying asthma are more likely to 
be treated with antibiotics prior to the asthma diagnosis being made. This would tend to bias 
results upward.  
 
(Other) reverse causality bias 
Other reverse causality bias can occur more generally when temporality of exposure (the 
hypothesized causal variable) and outcome is ambiguous. This could happen in a study of 
antibiotic exposure and asthma if (a) exposure and outcome ascertainment took place at or near 
the same time (e.g., in a cross-sectional study), or (b) if outcome ascertainment were for 
prevalent asthma or history of asthma.
14
  
 
Confounding bias by indication 
Confounding by indication
108
 can arise when the indication for treatment is an 
independent risk factor for the outcome. It can occur if infants are prescribed antibiotic treatment 
for an illness (e.g., infection with RV or RSV
20,21
) which is an independent risk factor for 
asthma. In such a scenario, risk factors for asthma would be an indication for antibiotic 
prescribing. In an analysis of this scenario, the association between antibiotic prescribing and 
asthma incidence would be confounded by the risk factor, leading to upward bias.  
 
12 
(Other) confounding bias 
 Confounding bias
109
 can arise when an independent risk factor for the outcome varies 
across levels of exposure and is not a causal intermediate between exposure and outcome. There 
are many ways in which confounding bias could occur in a study of antibiotics and asthma. For 
example, individuals in large cities receive more antibiotic prescriptions than those in rural areas; 
likewise, living in urban environments increases risk of asthma independently of antibiotic 
prescribing. A crude analysis of a random subset of the source population, comparing exposed 
versus unexposed regardless of home location, would therefore be confounded by home location 
and the magnitude of this confounding would be, in part, dependent on the proportion of the 
source population living in urban environments. 
  
Selection bias 
 Selection bias
110
 can arise when the relation between exposure and outcome in a study 
population differs from the relation between exposure and outcome in the target population. 
Assuming no other bias, if selection is associated with exposure and outcome, then absolute and 
relative estimates will be biased; if selection is associated with exposure only, then relative 
estimates will be valid; if selection is independent of exposure and outcome, then absolute and 
relative estimates will be valid. Selection bias could occur in a study of antibiotics and asthma if, 
for example, the study population contained a higher proportion of infants with parental history 
of asthma than the target population. In this setting, their underlying characteristics and risk for 
asthma would probably be different from those in the overall target population. 
  
13 
Recall bias 
 Recall bias
111
 arises in cross-sectional or retrospective studies when reporting of exposure 
occurs differentially with respect to the outcome or other characteristics. This could arise in a 
cross-sectional or case-control study of antibiotics and asthma in which a parent of an asthmatic 
child might be more likely to report early antibiotic exposure than a parent of a non-asthmatic 
child,
108
 leading to upward bias. Likewise, for children with and without asthma, poor recall of 
antibiotic exposure (e.g., among parents with older or multiple children) could result in non-
differential misclassification bias toward the null.  
  
Immortal time bias 
Immortal time bias
112,113
 can arise when exposure categories are assigned follow-up time 
during which the outcome could not have occurred. When it occurs, it usually results in 
downward bias, as individuals who end up classified as exposed must have survived free of the 
outcome for a nominal period in order to have received their classification as exposed. 
 
Detection bias  
 The general problem of detection bias is that diagnosis and treatment of an outcome may 
vary across levels of exposure.
114
 It can arise when a disease is underreported or 
underdiagnosed,
114
 as asthma has been for decades.
115,116
 There are multiple potential 
frameworks within which detection bias can occur, as detailed below. 
 
14 
Detection bias type 1 – Unmasking bias 
Unmasking bias or detection signal bias
114,117,118
 can arise when an exposure induces 
symptoms that lead to a search for disease and potential diagnosis of the outcome. This is similar 
to protopathic bias mentioned earlier – which can arise when underlying preclinical symptoms of 
the outcome of interest affect the treatment of interest – but the two biases are distinct from one 
another because unmasking bias occurs based on the extent of searching to detect and diagnose 
an outcome related to symptoms which were observed following treatment. In the context of 
antibiotics and asthma, this could occur if a patient infected with RSV showed signs of wheeze,
21
 
but was mistakenly treated with antibiotics for a suspected bacterial infection. If the viral 
infection were persistent and wheeze symptoms progressed,
41
 then the antibiotic would likely be 
recognized as ineffective – despite remaining in healthcare claims records – and the rule-out 
diagnosis of bacterial infection would likely be considered untrue or insufficient. As wheeze 
symptoms may be persistent,
41
 the practitioner could prescribe treatment for a diagnosis of 
asthma; in such a scenario, the record of an antibiotic prescription would be an artefact of the 
practitioner’s differential diagnosis method rather than as a cause of asthma.  
 
Detection bias type 2 – Diagnostic suspicion bias 
Diagnostic suspicion bias
114,118
 can arise when a practitioner’s knowledge of a patient’s 
exposure history affects the practitioner’s diagnostic process and decision-making. With regard 
to antibiotics and asthma, this could occur if patients presenting with symptoms indicative of 
potential (but not certain) asthma and were diagnosed with or without asthma differentially based 
on practitioners’ knowledge of the patient’s prior antibiotic exposure. In the proposed study, 
diagnostic suspicion bias is possible because practitioners can review treatment histories and the 
15 
probability of asthma diagnosis could be increased in the exposed because of their awareness of 
the ‘hygiene hypothesis.’ This would lead to upward bias.118  
 
Detection bias type 3 – Disease reporting bias 
Disease reporting bias
114
 can arise when a patient’s awareness of exposure influences 
their reporting of symptoms or disease to their practitioner. Not to be confused with recall bias, 
wherein exposure reporting varies differentially by outcome status, disease reporting bias occurs 
when outcome classification varies differentially by exposure status. This could occur in studies 
of infant antibiotic exposure and asthma if a parent were exposed to the ‘hygiene hypothesis’ or 
developed other beliefs about antibiotics subsequent to their infant’s exposure. If the child 
experienced respiratory distress, the parent could be more willing to seek care for their child out 
of concern for potential asthma. Given a similar child with identical respiratory symptoms, 
another parent with (a) different beliefs about antibiotics or (b) different memory of the child’s 
antibiotic exposure history could have less urgency – or no urgency – to seek care. There are 
multiple directions in which this bias could manifest, the combination of which would likely lead 
to minimal impact on inference. 
 
(Other) outcome misclassification bias 
 Outcome misclassification bias
119,120
 can occur when the sensitivity or specificity of the 
outcome assignment algorithm is imperfect. Outcome classification can be correlated with 
exposure status or may be independent of it, and the relation between outcome classification and 
exposure status can have major implications on the characteristics and interpretation of resulting 
biases. Absolute measures of effect will likely be biased if either sensitivity or specificity is 
16 
imperfect, because the true incidence of disease in each exposure group will be incorrectly 
estimated. However, relative measures can be robust to non-differential outcome 
misclassification bias if specificity is perfect (i.e., no false positives) – regardless of sensitivity – 
because misclassification will be proportional across exposure groups. As specificity decreases 
in such settings, bias increases independently with decreasing outcome prevalence and 
decreasing sensitivity. In a study of antibiotic exposure and asthma in a large population, 
outcome misclassification bias of relative effect measures could arise if a large proportion of 
individuals without asthma were incorrectly classified as having asthma. This bias would be 
largely non-differential with respect to antibiotic exposure in early life and would likely lead to 
bias toward the null; resulting inference could therefore misrepresent true effects as null or 
attenuated. 
 
2.3. CURRENT EPIDEMIOLOGIC EVIDENCE IS CONFLICTING REGARDING THE 
POTENTIAL ASSOCIATION BETWEEN EARLY LIFE ANTIBIOTIC EXPOSURE AND 
INCREASED RISK OF ASTHMA.  
Antibiotics are largely effective for treatment of specific bacterial infections and 
suppurative complications.
32,40,102
 Following exposure to antibiotics, however, bacterial flora in 
the gut are depleted and disrupted.
30
 In addition to increasing bacterial resistance at the 
population level,
32,40,44,99,121,122
 unnecessary antibiotic use during infancy and childhood may be 
harmful to children and increase their risk of atopic immune response and asthma.
14,32,123
  
Several epidemiologic studies have assessed the association between early antibiotic use 
and atopic response broadly defined;
28
 some provided evidence for an association
26,124
 whereas 
others provided evidence for no association.
124–127
 Studies finding no evidence of such an 
17 
association did not control adequately for potential confounding by parental history of 
atopy
125,126
 or frequency of doctor visits during childhood.
124,125
 
Over the last 15 years, numerous epidemiologic studies have examined the broad 
association between childhood antibiotic exposure and asthma;
13,14,128
 however, all of these 
studies were limited by intractable biases, and existing literature provides conflicting evidence of 
the presence or absence of such an association.
13,14,19,28
  
Regarding asthma specifically, results of epidemiologic studies since 1999 have been 
conflicting and subject to myriad potential biases. With one exception,
129
 cross-sectional 
studies
11,130–135
 provided consistent evidence of a deleterious association between antibiotic use 
and asthma. In the only case-control study on the subject, Martel et al.
93
 found evidence of an 
association (adjusted rate ratio 1.59; 95% CI 1.50–1.68) after adjusting for most potential 
confounding factors; however, that study was susceptible to multiple forms of detection bias, 
protopathic bias, recall bias and limited inference due to some strata of covariate cross-
classifications containing small counts. 
Along with other cross-sectional and case-control studies that likely suffered primarily 
from recall bias and protopathic bias, many cohort studies have already been conducted to assess 
the association between early antibiotic exposure and childhood asthma. They have provided 
evidence of a deleterious association between antibiotic use and asthma
7,26,75,92
 as well as no 
evidence of such an association.
13,124,136–143
 None of these studies controlled properly for all 
known confounding factors, and each one was subject to detection or confounding 
bias.
7,13,14,26,75,92,93,124,136–143
  
Despite its assessment of a well-defined cohort using a large administrative database and 
otherwise strong methods, one study by Marra et al.
7
 found a small association (adjusted hazard 
18 
ratio 1.12; 95% CI 1.08–1.16) and report evidence for a dose response by stating that the 
adjusted hazard ratio for >4 courses during infancy was 1.30 (95% CI 1.20–1.41). It should be 
noted that the average hazard ratio (HR) for incremental antibiotic course, calculated by hand by 
me from the publication, was 1.06. This study was unable to control sufficiently for potential 
confounding bias by family history of asthma, parental smoking or the presence of dust mites, 
which are some of the most important risk factors for asthma. This uncontrolled confounding 
could have biased the hazard ratio upward.  
In a small cohort (n=424), Su
140
 found an association (odds ratio, OR 1.5) for a dose-
response relation between infant antibiotic exposure and prevalent or past asthma. This study 
was susceptible to recall bias (because exposure and outcome information were provided by 
parent interview) and reverse causality (because incident asthma was not ascertained). This study 
did suggest that a potentially important control variable to minimize confounding by indication is 
the number of illness visits to a practitioner.
140
  
In a 2011 retrospective ancillary study of the Perinatal Risk of Asthma in Infants of 
Asthmatic Mothers prospective cohort study in southern New England, Risnes reported a 
deleterious association for antibiotic exposure in the first 6 months and asthma at 6 years 
(adjusted odds ratio, aOR 1.52; 95% CI 1.07–2.16), and evidence of a dose-response relation 
(average OR for incremental antibiotic course, calculated by hand from the publication, was 
1.31).
26
 It also found that the association was strongest in children without family history of 
asthma.
26
 This study minimized protopathic bias by having theoretically distinct exposure and 
outcome at-risk periods (i.e., infants diagnosed with asthma before 6 months of age were 
excluded). To minimize confounding by indication and detection bias, this study also reported 
similar increased risk of asthma for antibiotic exposure among a subgroup of children who had 
19 
no record of lower respiratory tract infection (LRTI) or wheeze during the first year of life (aOR 
1.78; 95% CI 1.12–2.81).144 To assess potential confounding by parental history of asthma, this 
study reported stratified results, and found an increased risk of asthma for antibiotic exposure 
among those whose parents had no history of asthma (aOR 1.89; 95% CI 1.00–3.58). Although 
this was consistent with model-adjusted results from a larger study,
75
 it was imprecise and based 
on a sample of only 47 asthma cases. Unfortunately, because exposure and outcome information 
was collected from parents when the child was 6 years old, this study was subject to recall bias. 
If antibiotic exposure were reported differentially by asthma status, then effect estimates could 
be biased upward away from the null. Additionally, this study did not assess different types of 
antibiotics; controlled for confounding by LRTI occurring during the first year of life, despite 
exposure ascertainment ending at 6 months; and did not control for the number of visits to a 
practitioner.  
Family history of immune dysfunction as well as other genetic and environmental 
characteristics that cluster within the family unit are primary causes of asthma.
14,20,26,36
 They are 
important confounding factors in this setting since they likely impact healthcare seeking 
behaviors and probability of redeeming antibiotic prescriptions. A recent study
36
 controlled for 
family characteristics by matching asthmatic children with their non-asthmatic siblings, and 
found evidence of increased risk for asthma after 2 years of age. 
All prior studies have estimated treatment effects using traditional outcome modeling 
adjustment methods, which assume homogeneity of antibiotic exposure effects across strata of 
the multidimensional covariate space, which is probably not a valid assumption. All prior studies 
which estimated dose-response relation did so by estimating a relative effect measure for any 
antibiotic exposure versus none and comparing that to the relative effect measure estimate for a 
20 
maximum number (e.g., >4) of courses during infancy to zero courses; such estimates do not 
translate to potential interventions and are therefore may not be appropriate to guide inference. 
 
2.4. SUMMARY 
Asthma is one of the most common chronic diseases in childhood, and poses a significant 
worldwide burden.
1–3
 Childhood asthma prevalence ranges 3-7% in Denmark,
4,5
 and 
approximately 10% of children take prescription medication to treat related symptoms.
6,7
 The 
prevalence of asthma, atopic response, and other allergic conditions has increased in recent 
decades,
1,2,8–12
 especially in industrialized areas,
3,13,14
 but reasons for these increases are 
unclear.
1,2,15–19
   
Many causes have been hypothesized to explain observed increases in asthma 
prevalence.
13,14
 Along with genetics,
20,21
 environmental factors,
20–24
 and viral infection,
20,21,24
 the 
“hygiene hypothesis”25  may also explain recent increases in the prevalence of childhood asthma, 
especially in industrialized countries.
14
 This controversial
19
 hypothesis asserts that adequate 
microbial exposure is important for developing proper immune response in early life.
19,26
 
Subsequently, child development in an overly hygienic environment – with lower exposure to 
microbiota – may induce elevated atopic response in children and elevated risk of the 
development of asthma.
7,14,27–29
  
 Antibiotic prescribing is common in children,
32,39
 but unnecessary use frequently occurs 
because bacterial and viral variants of upper respiratory tract infections are often clinically 
indistinguishable.
40–43
 Decreasing unnecessary antibiotic prescribing is a critical feature of 
clinical and public health approaches to stifle mounting threats of population-level bacterial 
resistance.
32,40,44–47
 In western industrialized countries in particular, increasing advocacy for 
21 
rational antibiotic prescribing has been associated with decreases in population-level antibiotic 
use.
48–51
 In addition, pneumococcal conjugate vaccination programs have been associated with 
decreased risk of acute otitis media and lower respiratory tract infections,
52
 two of the most 
common indications for antibiotics in children. 
 Given that antibiotics deplete and disrupt bacterial flora in the gut,
30,31
 they have long 
been suspected to cause increased risk of atopic immune response and asthma, particularly in 
children.
14,32
 Over the last two decades, numerous epidemiologic studies have examined the 
potential association between childhood antibiotic exposure and asthma,
12,14,26,33–37
 yielding 
conflicting results.
13,38
 Each prior study has been limited by intractable biases, including 
confounding by indication or other unmeasured factors, reverse causality, other protopathic bias, 
and recall bias. 
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CHAPTER 3: BIRTH COHORT EFFECTS ON ANTIBIOTIC PRESCRIBING DURING 
INFANCY AMONG CHILDREN BORN IN DENMARK, 2004-2012: A NATIONWIDE 
POPULATION-BASED COHORT STUDY
1
 
 
 
3.1.  INTRODUCTION 
 During early life, children are often prescribed antibiotics for bacterial infections 
including acute otitis media.
32,45,122
 Approximately 20%-50% of children’s antibiotic 
prescriptions are used to treat non-bacterial upper respiratory tract infections,
99,100,145
 for which 
they are largely ineffective.
29,32,40,100
 In western industrialized countries in particular, increasing 
advocacy for rational antibiotic prescribing has been associated with decreases in population-
level antibiotic use.
48–51
 In addition, pneumococcal conjugate vaccination programs have been 
associated with decreased risk of acute otitis media and lower respiratory tract infections,
52
 two 
of the most common indications for antibiotics in children. Taken together, there is a need to 
better characterize the changing patterns of antibiotic prescribing in children to inform future 
studies of antibiotic effectiveness and safety. 
 Although several studies have assessed trends in early life antibiotic prescribing, they 
have focused on estimating rates in cross-sectional population samples. Such studies
49,50,145–150
 
count multiple prescriptions per child and tend to present results for coarsely defined subgroups 
(e.g., age 0-4 years) or for subgroups defined by exogenous variables (e.g., during the year 
2010). Further, studies of rates implicitly estimate the frequency with which providers 
                                               
1
 This chapter was submitted to BMJ on 2 August 2016. 
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prescribe/dispense antibiotics to groups of children. In contrast, studies of risk aggregate 
individual-level data to elucidate which well-defined subgroups redeem prescriptions over 
specific follow-up intervals. Currently, data are limited regarding cohort effects on the risk of 
overall and medication-specific antibiotic use during early childhood. 
In Denmark, the Danish Health and Medicine Authority’s Institute for Rational 
Pharmacotherapy (IRF), a government institute, issued a nationwide bulletin to general 
practitioners in April 2007 with guidelines for rational antibiotic prescribing.
47
 The bulletin 
stated that antibiotics nominally affect the duration of acute otitis media infection and do not 
prevent adverse sequelae (e.g., mastoiditis or recurrent acute otitis media).
47
 It recommends that 
if the decision is made to prescribe antibiotics for acute otitis media, that primary treatment be 
with penicillin V (a narrow-spectrum antibiotic
81
), and amoxicillin (a broad-spectrum 
antibiotic
81
) be used only after failure of penicillin V.
47
 Following this bulletin, the 7-valent 
pneumococcal conjugate vaccine (PCV7) was added to the Danish childhood vaccination 
program on 1 October 2007, and the 13-valent vaccine (PCV13) was phased in starting on 19 
April 2010.
53–55
 No studies to date have evaluated the impact of these events on antibiotic 
prescribing in Denmark during the first year of life (henceforth, “infancy”). 
 We characterized overall and medication-specific measures of the risk, rate, and burden 
of antibiotic prescribing during infancy. Our primary objectives were to estimate birth-month 
and birth-season cohort effects on antibiotic prescribing during infancy in Denmark, and to 
examine the potential impacts of the IRF bulletin and the PCV7 and PCV13 vaccination 
programs on population-level antibiotic prescribing trends across birth cohorts over time.  
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3.2. METHODS 
The study population for this nationwide cohort study included all live births occurring in 
Denmark from 1 January 2004 to 31 December 2012. Children who survived less than one full 
day were excluded. We used each child’s unique ten-digit personal registration number (CPR-
number) to link their individual-level data across multiple registries.  
 
Data from the Medical Birth Registry and Civil Registration System 
We identified live births using the Danish Medical Birth Registry (MBR), which contains 
records of all live births in Denmark since 1973.
151
 We included children in the study cohort 
even if their MBR record did not list a father’s CPR number. We excluded children from the 
cohort in the following circumstances: (1) the CPR number in the MBR for the child or mother 
could not be linked to the Danish Civil Registration System (CRS), which contains information 
on vital status and migration
152
; (2) the place of childbirth or residence in Denmark could not be 
ascertained; (3) the child’s sex or date of birth was inconsistent across registries; or (4) a record 
for a redeemed prescription drug preceded a child’s date of birth. We examined the remaining 
cohort of children from date of birth until death, emigration, or for 365 days.  
 We grouped children by week, month, season (winter: December-February; spring: 
March-May; summer: June-August; autumn: September-November), and year of birth. We 
defined 52 weeks in the year based on 7-day increments. Exceptions to the 7-day definition for 
the week of birth variable were as follows: (1) February 29 was always grouped into week 9 so 
that every four years there were 8 days in week #9; and (2) week #52 always contained 8 days 
(24-31 Dec).  
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We used data from the MBR to identify characteristics of the mother, pregnancy, and 
birth event. We ascertained demographic information from the MBR and CRS. After obtaining a 
historical list of hospitals from the Health Care Classification System
153–155
 
(http://www.medinfo.dk/sks/brows.php, ftp://filer.sst.dk/filer/sks/data/skscomplete/), we 
conducted online searches to identify each hospital’s municipality and region, and classified each 
hospital as university-affiliated or not. We assigned geographic locations by municipality and 
region, and used national census data taken on 1 January 2012 (available from Statistics 
Denmark, http://www.StatBank.dk/bev22) to classify each municipality with regard to 
population density (number of residents per square kilometer).  
 
Data on antibiotics 
We used the Danish National Health Service Prescription Database to identify all 
prescriptions redeemed nationwide in community pharmacies and hospital-based outpatient 
pharmacies from 1 January 2004 to 31 December 2013.
156
 We identified antibiotic prescriptions 
using Anatomic Therapeutic Chemical (ATC) J01 codes, which include antibiotics that are 
administered for uptake through the circulatory system (as opposed to topically). We classified 
antibiotics by chemical substance (henceforth, “medication”), and further classified each 
medication as either broad- or narrow-spectrum using definitions set by Denmark’s Statens 
Serum Institut (http://www.medstat.dk/en, “Groups of Medicines” portal).  
   
Overall and medication-specific antibiotic prescribing (risk, rate, burden) 
 To describe how overall and medication-specific antibiotic prescribing differed across 
birth-year cohorts, we examined three measures of antibiotic prescribing: (1) one-year risk of at 
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least one redeemed antibiotic prescription during infancy, estimated as the complement of the 
Kaplan-Meier survival function (henceforth, “risk”); (2) incidence rate of redeemed antibiotic 
prescriptions, allowing for multiple redeemed prescriptions per infant (henceforth, “rate”); and 
(3) one-year burden of antibiotic prescriptions, based on the number of total days supplied for 
redeemed antibiotic prescriptions throughout infancy. For rate and burden measures, we 
computed each medication’s share of the overall measure, i.e., the proportion of the total number 
of prescriptions (for the rate) or days supplied (for the burden) for each drug. We calculated 99% 
confidence intervals (CIs) for risk (using pointwise intervals at one year of follow-up), rate, and 
burden estimates, and compared overall and medication-specific measures by birth-year cohort. 
 
Birth-season cohort and time to first redeemed antibiotic prescription during infancy 
 To assess the impact of birth-season on age at first redeemed antibiotic prescription, we 
estimated time to first redemption during infancy and compared results across birth-season 
cohorts. Stratifying by birth-month and birth-season (categorized as described above) in separate 
analyses, we used age in months as the time scale and first redeemed antibiotic prescription as 
the event of interest. For each stratum of birth-season or birth-month, we estimated the hazard 
function for first redeemed antibiotic prescription and the risk function based on the complement 
of the Kaplan-Meier survival function, which accounted for censoring at death or emigration. 
 
Interrupted time series analysis 
 To assess changes in the trend of antibiotic prescribing over time, we used segmented 
linear regression analysis of an interrupted time series data structure.
157–160
 Separately for each 
birth-week cohort, we estimated the one-year risk of redeeming at least one antibiotic 
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prescription during infancy, redeeming at least one amoxicillin prescription during infancy, and 
redeeming at least one penicillin V prescription.  
In our study, interruptions denoted time points when we hypothesized that a population-
level change occurring in Denmark could have altered antibiotic use among infants, depending 
on whether they were born before or after the interruption. We identified five interruptions, 
detailed in Table 3.1: (1) the IRF bulletin
47
; (2) the PCV7 “catch-up” vaccination program53,55; 
(3) the standard PCV7 vaccination program
53,55
; (4) the transition from PCV7 to the 13-valent 
pneumococcal conjugate vaccine (PCV13)
55
; and (5) the time when PCV13 program became 
predominant.
55
 Because the IRF bulletin and PCV7 “catch-up” program occurred within one 
month, we consolidated them and assigned them to 1 May 2006, thus allowing a one-month lag 
for dissemination of the bulletin.  
 To control for confounding by seasonality in the interrupted time series analysis, we used 
a transformed cosine periodic function
161
 with terms for sin(2πi/52 radians) and cos(2πi/52 
radians), where i denotes the week of birth during the year, i={1, 2, ..., 52}.
162,163
 Our full 
segmented linear regression model was thus specified as:  
Rw = α + β0(time after 1 Jan 2004)w + β1(time after 1 May 2006)w + β2(time after 1 Jul 2007)w + 
β3(time after 19 Jan 2010)w + β4(time after 1 Oct 2010)w + β5(sin(2πi/52)) + β6(cos(2πi/52)), 
where the dependent variable, Rw, was the one-year risk of at least one redeemed antibiotic 
prescription during infancy for children born in week w of the study period, w={1, 2, ..., 468}. 
The trend estimate for any segment in the time series was equal to the baseline trend estimate 
(?̂?0) plus ?̂? estimates for all trend changes at interruptions preceding the segment of interest; e.g., 
for the third segment (1 Jul 2007 until 19 Jan 2010) the estimate was equal to ?̂?0+?̂?1+?̂?2. (Please 
see Appendix A for supplementary methodological detail on the interrupted time series analysis.) 
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 All statistical analyses were conducted using SAS software versions 9.2 and 9.3 (SAS 
Institute, Inc.; Cary, North Carolina USA). Figures were created using R software version 3.2.1 
(R Foundation for Statistical Computing; Vienna, Austria) and Inkscape version 0.91 
(www.inkscape.org). This study was approved by the Danish Data Protection Agency (record 
number 2013-41-1790), the Danish Statens Serum Institut (FSEID-00001450), and the 
institutional review board at the University of North Carolina at Chapel Hill (study 13-3155). 
 
 
 
3.3.  RESULTS 
The final study population included 561,729 live births in Denmark occurring from 1 
January 2004 to 31 December 2012. Table 3.2 reports demographic and birth characteristics of 
infants in the study population. There were 333,298 infants (59.3% of the total cohort) with at 
least one redeemed prescription for any drug during their first year, 66% of whom had at least 
one redeemed antibiotic prescription (n=220,655). Antibiotic prescriptions (n=403,886) 
accounted for 46% of all drug prescriptions (n=878,641) redeemed during infancy.  
 
Overall and medication-specific antibiotic prescribing 
The overall risk of at least one redeemed antibiotic prescription during infancy was 
39.5% (99% CI: 39.3, 39.6). Table 3.3 shows the one-year risk of having at least one redeemed 
antibiotic prescription during infancy, stratified by child and maternal characteristics. Boys were 
at higher risk than girls, birth-month-specific risk peaked from February through May, and risk 
decreased across the study period. Maternal smoking during pregnancy was associated with 
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increased risk, and children born to mothers who requested a cesarean delivery were at elevated 
risk compared to the rest of the population. Risk was not associated with gestational age at birth 
or birth weight. Geographically, the Zealand and Southern regions had the highest risk, the 
Central region had the lowest, and higher population density was associated with lower risk 
(Figure 3.1).  
The overall rate of antibiotic prescribing during infancy was 72 redeemed prescriptions 
per 100 infant-years of follow-up. The overall burden was 67 daily doses per 10,000 infant-days. 
Table 3.4 shows the risk, rate, and burden of selected antibiotic medications among children in 
the study. Out of 22 antibiotic medications prescribed to infants in Denmark during the study 
period, amoxicillin and penicillin V together accounted for roughly 90% of the prescriptions.  
Overall one-year risks and rates decreased across birth-year cohorts (Appendix B); 
however, the overall burden of antibiotic prescribing remained stable, ranging from 61 to 75 
daily doses per 10,000 infant-days. Amoxicillin’s share of the overall rate and burden increased 
across cohorts from 2004 through 2012, while penicillin V’s share decreased. Erythromycin was 
the third most common antibiotic prescribed to infants during the study period, but its share of 
total antibiotic prescriptions was <0.5% by 2012.  
 
Birth-season cohort and time to first redeemed antibiotic prescription during infancy 
 Figures 3.2 and 3.3 provide complementary depictions of the relation between birth-
season cohort, age, and time to first redeemed antibiotic prescription during infancy. The hazard 
of a first redeemed antibiotic prescription peaked as infants experienced the months between 
December and March (Figure 3.2A). Comparing birth-month cohorts as they experience different 
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sequences of seasons through the first year of life, Figure 3.2B shows variation by birth-month 
cohort in both the profile of the risk function and the magnitude of the risk at one year.  
 Figure 3.3 shows hazard and risk as a function of age, collapsing months of birth into 
four birth-season cohorts and anchoring the x-axis at birth. The hazard of a first redeemed 
antibiotic prescription increased with age through 12 months and that hazard functions peaked in 
February, leading to variation in hazard by birth-season (Figure 3.3A). Subsequently, risk 
profiles through infancy also varied by birth-season cohort, resulting in differences between 
birth-season cohorts in the relation between age and risk (Figure 3.3B). Infants born in the spring 
had the lowest risk through 6 months of age (6.5%, 99% CI: 6.3%, 6.6%) and the highest through 
12 months (44.8%, 99% CI: 44.5%, 45.2%), whereas infants born in the autumn had the highest 
risk through 6 months of age (11.5%, 99% CI: 11.2%, 11.7%) and the lowest through 12 months 
of age (34.2%, 99% CI: 33.9%, 34.6%). Subsequently, interpretation of differences in risk 
between birth-season cohorts was determined in part by the age at which two pointwise risks 
were compared. 
 
Interrupted time series analysis 
 Figure 3.4 and Table 3.5 show risk and trend estimates from our interrupted time series 
analysis. The overall birth-season-adjusted risk of at least one redeemed antibiotic prescription 
under our segmented regression model decreased from 40.7% (births in 2004) to 34.6% (births in 
2012). For children born from 1 January 2004 until 1 May 2006, there was an increasing trend 
for amoxicillin prescriptions, but no change for penicillin V. After interruption 1, when the IRF 
bulletin was published and the PCV7 “catch-up” vaccination program was initiated, risk 
decreased for prescriptions of both amoxicillin and penicillin V. The trend for amoxicillin began 
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to rebound after standard enrollment began for the PCV7 program 14 months later, but decreased 
starting at the PCV13 rollout through the end of the study period. Prescribing of penicillin V 
changed little for children born after 1 July 2007, but decreased after standard PCV13 enrollment 
began. Interruption effects were an order of magnitude smaller than birth-season cohort effects. 
Our sensitivity analysis demonstrated that adding a 7-month lag affected the trend for 
amoxicillin but not for penicillin V (Appendix C). The baseline trend for amoxicillin from 1 
January 2004 until 30 April 2006 was similar with the lag (0.14% per month; 99% CI: 0.10%, 
0.19%) and without the lag (0.17% per month; 99% CI: 0.13%, 0.21%). Without the lag, the 
primary analysis showed a decreasing trend from 1 May 2006 until 1 July 2007 (-0.22% per 
month; 99% CI: -0.29%, -0.16%). In contrast, the sensitivity analysis estimated a trend near 
unity starting before the lag through 1 January 2007 (0.03% per month; 99% CI: -0.13%, 0.18%), 
followed by a precipitous decreasing trend after the lag through 1 July 2007 (-0.58% per month; 
99% CI: -0.79%, -0.37%). Trend interpretation did not change in all other sensitivity analyses 
(Appendix C). 
 
 
 
3.4. DISCUSSION 
 In this nationwide population-based cohort study from 2004 through 2012, we observed 
decreases over time in the proportion of infants born in Denmark who received antibiotics during 
their first year of life, and in the total number of antibiotic prescriptions per infant-year. Yet, 
over time, those infants who received antibiotic prescriptions received increasing numbers of 
prescriptions and days supplied. Taken together, the increasing concentration of antibiotic 
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prescribing in a shrinking proportion of the infant population resulted in little change over time 
in population-level antibiotic burden. Amoxicillin, a broad-spectrum antibiotic, became 
increasingly prominent over time, while penicillin V prescribing decreased each year after 2005. 
In our analysis of time to first redeemed antibiotic prescription, we observed that infants’ first 
antibiotic prescriptions occurred more frequently with increasing age, and during winter. As a 
result, the association between birth-season and risk of redeeming an antibiotic prescription 
varied with increasing age. In our interrupted time series analysis, we found that risk of at least 
one redeemed amoxicillin prescription was dynamic during the study period, with decreasing 
trends after the IRF bulletin and the PCV7 “catch-up” program, and after PCV13 program 
initiation. 
 
Strengths and limitations of this study 
This study has several strengths. The registry databases facilitated our implementation of 
a large nationwide population-based cohort study of all children born in Denmark, during this 
nine-year period when antibiotic prescribing practices were in transition. The tax-supported 
healthcare system for the entire Danish population includes free access to medical care and 
partial reimbursement of prescribed medications,
152
 leading to minimal disparity in access to 
healthcare services in our study population. Our study linked individual-level data across 
multiple registries to jointly assess infants’ records of redeemed antibiotic prescriptions and their 
demographic and other health-related characteristics. Furthermore, the registries that we used for 
this study contain accurate data on the date and medication type of redeemed antibiotic 
prescriptions, date of birth, residence, and other variables that we assessed.
151,152,156
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 Our estimates for the total birth-season cohort effect on antibiotic prescribing are unlikely 
to be confounded, since season of birth is not affected by other risk factors for antibiotic use 
during infancy (e.g., birth order, sex, gestational age at birth).
164
 Throughout the study period, 
there were no changes in population-level characteristics of children born in Denmark; further, 
no new antibiotic formulations were introduced during the study period, and administration of 
antibiotic prescriptions to infants did not change. This level of stability limits potential for biased 
interpretation in the interrupted time series study due to confounding and measurement bias or 
the effects of co-interventions.
158,165
 
This study also has some limitations that should be considered when interpreting results. 
We lacked data on indication since the large majority of antibiotics prescribed to infants are 
administered by general practitioners, who are not mandated to record a diagnosis to issue 
prescriptions.
116
 This limited our ability to explore infection trends that might have caused 
changes in antibiotic prescribing over time or across population subgroups. Second, data on 
redeemed antibiotic prescriptions did not provide information on medication ingestion
156
; 
however, our study question and interpretation of data focused on antibiotic prescribing as the 
event (rather than taking the drug), and focused primarily on infants’ first redeemed antibiotic 
prescription. We note limited ability to compare results to a control population in the interrupted 
time series analysis,
159,165
 because the IRF bulletin and PCV programs pertained to the 
nationwide population of children born in Denmark. Trends over time in antibiotic prescribing 
are driven by the prevalence and infectiousness of circulating illnesses; although we controlled 
for seasonality and carefully selected relevant interruptions and their time at onset, our results 
may be biased by our inability to account for underlying differences in circulating illness from 
year to year, or other unmeasured temporal influences.  
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Interpreting results compared with other studies  
Our risk and rate estimates corroborate previous findings from substantially smaller 
studies on the risk and rate of overall antibiotic prescribing among infants in Europe.
139,149
 We 
provide new information on overall and medication-specific patterns of antibiotic prescribing, 
including the correlation between measures of risk, rate, and burden, and how they changed 
across nationwide birth-year cohorts in Denmark over a nine-year period.  
 Prior studies
49,50,146–150
 of antibiotic prescribing have focused on estimating rates. 
Although we described rates (redeemed prescriptions ÷ person-time) and burden (days supplied 
÷ person-time), we focused primarily on estimating the risk of redeeming at least one antibiotic 
prescription during infancy. Risk provides information about the aggregate of individual infants 
with redeemed antibiotic prescriptions – and those without prescriptions – by posing the research 
question, “in a well-defined cohort, which children had a redeemed antibiotic prescription in 
their first year, and when was the first prescription redeemed?” In contrast, rate and burden 
estimates require additional assumptions
166,167
 and tend to shift the focus of the research question 
to the population level, asking “how many redeemed prescriptions (or days supplied) were 
prescribed for children in a given population subgroup, defined by calendar time or another 
characteristic?” We recognize that each of these questions has merit depending on the setting; 
however, if an investigator wishes to assess individual-level determinants of antibiotic 
prescribing, then the risk estimator is of primary importance.  
 Results regarding birth-season effects tracked with disease patterns of acute otitis media, 
a prominent indication for antibiotic treatment, which peaks in the winter and for children over 6 
months old.
122
 Only two prior studies
147,148
 have considered seasonal differences in antibiotic 
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prescribing in children, also showing that antibiotic prescribing peaked in winter. However, as 
those studies focused on estimating the rate, the interpretation of seasonality pertained to time 
periods of peak usage rather than to intrinsically different cohorts of children (i.e., defined by 
birth-season). Other prominent studies of antibiotic prescribing in children
50,99,139,146,149
 have not 
explicitly assessed seasonal differences.  
 Using detailed individual-level nationwide data on antibiotic prescribing, our analysis 
provides new information on risk and time to first redeemed antibiotic prescription, which are 
important estimators for public health. These new findings on birth-season cohort effects may 
inform two aspects of future pediatric studies examining antibiotics as the exposure of interest: 
(1) antibiotic exposure status may differ meaningfully between children born in different 
seasons, and (2) birth-season differences in age at first antibiotic use may modify the effect – 
intended or unintended – of antibiotic treatment, given increased vulnerability to both short- and 
long-term effects of microbial insults in early life.
24,168
 Investigators of antibiotic exposure 
effects should consider these cohort effects on effect modification or confounding bias. 
 This is the first study to explicitly evaluate the impact of the IRF bulletin (in 2007) and 
pneumococcal conjugate vaccines (from 2007 onward) on antibiotic prescribing patterns in the 
infant population of Denmark. It is unclear why the amoxicillin trend rebounded for births after 
July 2007, following implementation of the PCV7 program. Potential explanations include (1) 
changes in the prevalence of circulating illnesses from 2007 to 2010, particularly among children 
born in late 2009 whose elevated risk appears unique compared to the overall trend in the two 
prior years; (2) a temporary minimum threshold effect
158
 in 2007-2008; and (3) limited impact of 
PCV7 on infection prevention. 
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The delayed decrease in the trend for amoxicillin after allowing a 7-month lag could 
result from a stronger lagged (versus immediate) effect of either the IRF bulletin or the PCV7 
“catch-up” program, or both. If the lagged decrease were caused by the IRF bulletin, then the 
bulletin would have affected children born after 1 January 2007 more than those born earlier. 
This would correspond to a larger effect on infants no older than 3 months old when the bulletin 
was published compared to infants who were 3-12 months old at that time. Given that risk 
increased with age during infancy, a discernible impact of the bulletin would likely have 
occurred some months after its publication. At the same time, a strong lagged effect of the PCV7 
“catch-up” program would have been plausible if the regular PCV7 program had been associated 
with decreasing risk.  
This analysis builds on prior studies of antibiotic prescribing in early childhood
50,99,139,146–
149
 by (1) using granular time scales to assess seasonal and secular trends; (2) examining 
prescribing in the well-defined infant population of Denmark; (3) assessing birth-season cohort 
effects on time to first redeemed antibiotic prescription; and (4) invoking quasi-experimental 
methods to explicitly assess potential changes in prescribing due to population-level policies or 
events. The birth cohort effects described in this study have implications for design and analysis 
of future studies of antibiotic safety and effectiveness in children that span multiple birth-season 
or birth-year cohorts, since these clear differences in antibiotic use may render some subgroups 
inherently more susceptible to downstream side effects than others. 
  
Conclusions 
Children’s season of birth impacted both their overall risk of redeeming an antibiotic 
prescription during infancy and their age at first redeemed antibiotic prescription. Amoxicillin 
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prescribing was dynamic over the study period, but decreased after distribution of a bulletin on 
rational antibiotic use in general practice and the rollout of two nationwide pneumococcal 
vaccination programs. Finally, this study provides new information on the correlation between 
measures of risk, rate, and burden of antibiotic prescribing in the infant population. 
 
  
Table 3.1. Interruption time points for hypothesized population-level changes in Denmark related to antibiotic use among infants. 
Interruption 
Date of 
publication or 
rollout 
First birth cohort to 
experience potential 
interruption effect during 
infancy (negative lag) Intended effect and description of interrupting policy/event 
IRF bulletin 1 April 2007 1 April 2006 Bulletin to encourage rational antibiotic prescribing in general practice. 
For antibiotic treatment for acute otitis media, it recommended penicillin 
V for primary treatment and amoxicillin after treatment failure.
47
  
PCV7 “catch-up” 
program 
1 October 2007 1 May 2006 Cost-free enrollment in PCV7 program for children between 3-17 months 
of age on 1 October 2007. Vaccination intended to reduce incidence of 
invasive pneumococcal disease, pneumococci-related upper and lower 
respiratory infection, and transition of pneumococci in the general 
population. Children in this group who received their first PCV7 
vaccination before their first birthday were offered a second PCV7 course 
after an interval of at least one month, and a third course a minimum of 
two months after the second. Children who received their first course after 
their first birthday were offered one additional course at least two months 
after the first.
53–55
  
 
Standard PCV7 
program 
1 October 2007 1 July 2007 Cost-free enrollment in PCV7 program for children <3 months of age on 1 
October 2007, onward. Children in this group were offered a series of 
three PCV7 courses at 3, 5, and 12 months of age, concurrent with the 
DTaP/IPV/Hib vaccination.
53–55
 
Transition from 
PCV7 to PCV13 
19 April 2010 19 January 2010 Cost-free enrollment in PCV13 program for children <3 months of age on 
19 April 2010, onward; however, the Danish childhood vaccination 
program recommended using all PCV7 stocks before initiating PCV13 
administration. PCV13 dissemination was therefore gradual during 2010.
55
 
Standard PCV13 
program 
1 January 2011 1 October 2010 Cost-free enrollment in PCV13 program for children <3 months of age. 
After the gradual depletion of PCV7 stocks during 2010, PCV13 
utilization became predominant nationwide by 2011.
55
 
IRF = Institute for Rational Pharmacotherapy; PCV7 = 7-valent pneumococcal conjugate vaccination program; DTaP/IPV/Hib = Diphtheria, 
Tetanus, acellular Pertussis, Polio and Haemophilus influenzae type b; PCV13 = 13-valent pneumococcal conjugate vaccination program
3
8
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Table 3.2. Characteristics of infants born in Denmark, 2004-2012. 
 
Total study population  
(N = 561,729) 
  No. or (median) % or (IQR) 
Demographics 
  Sex of child 
  Female 273,839 48.7 
Male 287,890 51.3 
Mother's age at birth (years) (31) (27, 34) 
Month of birth 
  January 45,744 8.1
February 43,229 7.7 
March 47,038 8.4 
April  45,113 8.0 
May 47,488 8.5 
June 48,187 8.6 
July 50,811 9.0 
August 50,745 9.0 
September 48,539 8.6 
October 47,197 8.4 
November 44,376 7.9 
December 43,262 7.7 
Year of birth 
  2004 64,146 11.4 
2005 63,757 11.4 
2006 64,669 11.5 
2007 63,539 11.3 
2008 64,556 11.5 
2009 62,485 11.1 
2010 63,055 11.2 
2011 58,386 10.4 
2012 57,136 10.2 
Born in university hospital 223,817 39.8 
Region of birth 
  Capital Region 190,832 34.0 
Zealand Region 70,089 12.5 
Southern Region 112,140 20.0 
Central Region 137,420 24.5 
North Region 51,248 9.1 
Population density of municipality of 
residence at birth (residents per km
2
) (177) (87, 794) 
Maternal characteristics 
  Parity or birth order (live+still births) 
  First pregnancy 246,191 43.8
Second 203,881 36.3 
Third 76,312 13.6 
Fourth 18,643 3.3 
Fifth or more 8,359 1.5 
Missing 8,343 
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No. of pregnancy visits to GP (3) (2, 3) 
No. of pregnancy visits to midwife (5) (4, 6) 
No. of pregnancy visits to specialist (0) (0, 0) 
Mother's pregravid weight (kg)* (65) (59, 75) 
Mother's pregravid BMI (kg/m
2
)† (23.0) (20.8, 26.0) 
Pregnancy and birth event 
  Singleton pregnancy 537,790 95.7 
Maternal smoking during pregnancy 
  Did not smoke 470,150 85.7 
Smoking, amount unknown 1,542 0.3 
Stopped smoking in first trimester 11,346 2.1 
Stopped smoking after first trimester 2,702 0.5 
Smoking, ≤5 cigarettes/day 19,471 3.5 
Smoking, 6-10 cigarettes/day 23,822 4.3 
Smoking, 11-20 cigarettes/day 17,286 3.1 
Smoking, >20 cigarettes/day 2,463 0.4 
Missing 12,947 
 Gestational age (weeks) at birth (40) (39, 41) 
Cesarean delivery for this birth 123,250 21.9 
Cesarean upon maternal request 15,695 2.8 
Operative vaginal delivery 45,183 8.0 
Suture to repair birth injury 210,068 37.4 
Birth weight (grams) (3500) (3150, 3850) 
Newborn transferred to NICU 51,964 9.3 
Respiratory aid in NICU 23,754 4.2 
Sepsis in child 8,989 1.6 
Congenital malformation 40,733 7.3 
Died during first year of life 1,073 0.2 
Emigrated during first year of life 2,807 0.5 
 
    
 
IQR = interquartile range; km = kilometer; GP = general practitioner; kg = kilogram; m = meter; 
BMI = body mass index; NICU = neonatal intensive-care unit 
* 5.2% of children had missing data for maternal pregravid weight. 
† 5.9% of children had missing data for maternal pregravid BMI. 
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Table 3.3. One-year risk of redeeming at least one antibiotic prescription during the first year of 
life according to selected characteristics of infants born in Denmark, 2004-2012. 
 At least one redeemed antibiotic prescription 
  No. Risk (%)* 99% CI 
Overall redeemed antibiotic prescriptions 220,655 39.5 39.3, 39.6 
≥1 broad-spectrum antibiotic prescription 147,594 26.3 26.1, 26.4 
≥1 narrow-spectrum antibiotic prescription 122,319 21.8 21.7, 21.9 
Demographics 
  
 
Sex of child 
  
 
Female 97,357 35.7 35.5, 36.0 
Male 123,298 43.0 42.8, 43.3 
Month of birth 
  
 
January 17,921 39.4 38.8, 40.0 
February 18,397 42.8 42.1, 43.4 
March 20,996 44.8 44.2, 45.4 
April  20,333 45.3 44.7, 45.9 
May 20,976 44.4 43.8, 45.0 
June 20,553 42.8 42.3, 43.4 
July 20,173 39.9 39.3, 40.4 
August 17,731 35.1 34.5, 35.6 
September 16,407 33.9 33.4, 34.5 
October 16,073 34.2 33.6, 34.8 
November 15,293 34.6 34.0, 35.2 
December 15,802 36.7 36.1, 37.3 
Year of birth 
  
 
2004 26,266 41.1 40.6, 41.6 
2005 26,281 41.4 40.9, 41.9 
2006 27,410 42.6 42.1, 43.1 
2007 24,491 38.7 38.2, 39.2 
2008 24,980 38.9 38.4, 39.4 
2009 24,917 40.1 39.6, 40.6 
2010 25,057 39.9 39.4, 40.4 
2011 21,455 36.9 36.4, 37.4 
2012 19,798 34.8 34.3, 35.4 
Region of birth 
  
 
Capital Region 73,926 39.0 38.7, 39.3 
Zealand Region 31,953 45.7 45.2, 46.2 
Southern Region 49,422 44.2 43.9, 44.6 
Central Region 45,891 33.5 33.2, 33.8 
North Region 19,463 38.1 37.6, 38.6 
Maternal characteristics 
  
 
Parity or birth order (live+still births) 
  
 
First pregnancy 85,570 34.9 34.7, 35.2 
Second 88,248 43.4 43.2, 43.7 
Third 31,785 41.8 41.4, 42.3 
Fourth 7,897 42.5 41.6, 43.5 
Fifth or more 3,730 45.0 43.6, 46.4 
Missing 3,425 
 
 
Pregnancy and birth event 
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Maternal smoking during pregnancy 
  
 
Did not smoke 180,423 38.6 38.4, 38.7 
Smoking, amount unknown 680 44.4 41.2, 47.7 
Stopped smoking in first trimester 4,581 40.5 39.4, 41.7 
Stopped smoking after first trimester 1,158 43.0 40.6, 45.5 
Smoking, ≤5 cigarettes/day 8,602 44.3 43.4, 45.3 
Smoking, 6-10 cigarettes/day 10,859 45.8 44.9, 46.6 
Smoking, 11-20 cigarettes/day 8,034 46.6 45.6, 47.6 
Smoking, >20 cigarettes/day 1,109 45.3 42.8, 47.9 
Missing 5,209 
 
 
Cesarean upon maternal request 6,956 44.4 43.4, 45.5 
Congenital malformation 17,528 43.6 42.9, 44.2 
       
 
CI = confidence interval 
* Risk estimates reflect each subgroup’s one-year cumulative incidence of at least one redeemed 
antibiotic prescription during infancy, based on the complement of the Kaplan-Meier survival function, 
which accounted for censoring at death or emigration. 
 
 Table 3.4. Redeemed antibiotic prescriptions by ATC code among infants born in Denmark, 2004-2012 (N=561,729).  
 
 
ATC = Anatomical Therapeutic Chemical classification 
Data not shown for the following antibiotics because of small numbers: ampicillin, pivampicillin, pivmecillinam, dicloxacillin, flucloxacillin, 
cefuroxime, meropenem, sulfamethizole, roxithromycin, tobramycin, ciprofloxacin, vancomycin, colistin, fusidic acid, and nitrofurantoin. 
* Spectrum classification defined by Danish Register of Medicinal Product Statistics, Statens Serum Institut (http://www.medstat.dk/en).  
† Risk estimates reflect medication-specific cumulative incidence of at least one redeemed antibiotic prescriptions for during infancy, based on the 
complement of the Kaplan-Meier survival function which accounted for censoring at death or emigration; the sum of medication-specific risks 
exceeds overall antibiotic risk because infants could redeem prescriptions for more than one type of antibiotic medication in their first year.  
‡ Rate = no. of redeemed prescriptions per 100 infant-years of follow-up  
§ Share of antibiotic rate = (no. of redeemed prescriptions) ÷ (total no. of redeemed prescriptions for all antibiotics) 
‖ Population-level antibiotic drug burden = days supply per 10,000 infant-days of follow-up  
¶ Share of antibiotic burden = (days supply) ÷ (total days supply for all antibiotics)        
          
 
 
  
No. of infants with ≥1 
redeemed antibiotic 
prescription 
 
No. of redeemed antibiotic 
prescriptions   Days supplied of antibiotic medication 
ATC code 
ATC level 5  
(medication) 
ATC level 4 
(subgroup) 
Spectrum 
classification* No. Risk (%)† 
 
No. Rate‡ Share (%)§  
Days 
supplied Burden‖ Share (%)¶ 
J01 All antibiotics All antibiotics All antibiotics 220,655 39.5  403,886 72 100.0  1,368,589 67 100.0 
J01CA04 Amoxicillin Penicillins, 
extended 
spectrum 
Broad 144,104 25.8  223,999 40 55.5  844,466 41 61.7 
J01CE02 Penicillin V β-lactamase 
sensitive 
penicillins 
Narrow 104,609 18.7  133,622 24 33.1  341,838 17 25.0 
J01CR02 Amoxicillin 
clavulanate 
Combinations 
of penicillins 
Broad 7,541 1.3  10,694 2 2.6  48,539 2 3.5 
J01EA01 Trimethoprim Trimethoprim, 
derivatives 
Narrow 1,362 0.2  2,555 0 0.6  6,643 0 0.5 
J01FA01 Erythromycin Macrolides Narrow 14,797 2.6  18,240 3 4.5  79,750 4 5.8 
J01FA09 Clarithromycin Macrolides Narrow 6,024 1.1  7,074 1 1.8  26,142 1 1.9 
J01FA10 Azithromycin Macrolides Narrow 3,363 0.6  4,127 1 1.0  8,496 0 0.6 
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 Table 3.5. Intercept and trend estimates with 99% confidence intervals (CIs) from segmented linear regression model for the risk (per 
100 children, %) of at least one redeemed antibiotic prescription during the first year of life among infants born in Denmark, 2004-
2012 (N=561,729). 
 
  Any antibiotic (J01)   Amoxicillin (J01CA04)   Penicillin V (J01CE02) 
Parameter Estimate*
 
(%) 99% CI   Estimate*
 
(%) 99% CI   Estimate* (%) 99% CI 
intercept 40.135 39.310, 41.960  23.490 22.766, 24.214  21.047 20.465, 21.630 
trend01Jan2004_30Apr2006† 0.090 0.045, 0.135  0.170 0.131, 0.210  -0.006 -0.038, 0.026 
trend01May2006_30Jun2007† -0.316 -0.390, -0.241  -0.224 -0.289, -0.159  -0.226 -0.278, -0.173 
trend01July2007_18Jan2010† 0.066 0.030, 0.102  0.089 0.057, 0.121  0.007 -0.019, 0.032 
trend19Jan2010_30Sep2010† -0.198 -0.324, -0.071  -0.317 -0.428, -0.206  -0.021 -0.110, 0.068 
trend01Oct2010_31Dec2012† -0.193 -0.243, -0.142  -0.138 -0.182, -0.094  -0.084 -0.120, -0.049 
sin(2πi/52) 5.521 5.209, 5.833  4.172 3.898, 4.445  2.899 2.679, 3.119 
cos(2πi/52) -1.690 -2.000, -1.380  -1.339 -1.610, -1.067  -1.066 -1.284, -0.847 
 
CI = confidence interval; i = week of birth during the year, i={1, 2, ..., 52}. 
* Estimates correspond to the risk (or change in risk) per 100 children. 
† Trend estimates are scaled to month intervals, corresponding to change in linear risk per month of calendar time for births occurring 
between boundary dates. 
4
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Figure 3.1. Geographic variation in population density and risk of redeeming at least one 
antibiotic prescripiton during the first year of life. (Panel A) Geographic variation in population 
density (in residents per square kilometer, km
2
) by municipality, taken from census data issued 
for 1 January 2012 (available from Statistics Denmark, http://www.StatBank.dk/bev22). (Panel 
B) Risk of redeeming at least one antibiotic prescription during the first year of life among 
infants born in Denmark, 2004-2012. Geographic areas are grouped by municipality (n=98) and 
region (n=5), assigned based on the location of residence following birth. For births that occurred 
before the 1 January 2007 reformation of governmental districts into 98 municipalities and 5 
regions, geographic data have been harmonized according to the current administrative structure. 
Artificial gaps separate the North, Central, and Southern regions; the Capital region is detailed in 
the inset and includes the island of Bornholm (to scale), located 160 km east-southeast of 
Copenhagen. Each region’s capital city is labelled and marked by a diamond. 
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Figure 3.2. Hazard and risk functions for antibiotic prescriptions during the first year of life, 
stratified by month of birth. (Panel A) Hazard functions for first redeemed antibiotic prescription 
by month during the first year of life, stratified by month of birth among children born in 
Denmark, 2004-2012. Each colored curve depicts a birth-month cohort’s hazard over one year of 
follow-up from birth, smoothed using a 7
th
-order polynomial function with 99% confidence 
bands (CB). For each month on the calendar time scale, black diamonds show the hazard of a 
first redeemed antibiotic prescription during that month averaged across all twelve birth-month 
cohorts; to avoid redundancy, each monthly average hazard is plotted only once. (Panel B) Risk 
function for at least one redeemed antibiotic prescription during the first year of life by month, 
stratified by month of birth among children born in Denmark, 2004-2012. The risk function was 
estimated as the complement of the Kaplan-Meier survival function, with 99% pointwise 
confidence intervals (CI) taken at each event time (assessed daily). 
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Figure 3.3. Hazard and risk functions for antibiotic prescriptions during the first year of life, 
stratified by season of birth. (Panel A) Hazard functions for a first redeemed antibiotic 
prescription by age (in months) and season of birth among children born in Denmark, 2004-
2012. Each hazard function is smoothed using a 20
th
-order polynomial function with 99% 
confidence bands (CB). Black diamonds represent the average hazard by age in months. (Panel 
B) Risk function for at least one redeemed antibiotic prescription, by age (in months) through the 
first year of life, stratified by season of birth, Denmark 2004-2012; the risk function was 
estimated as the complement of the Kaplan-Meier survival function, with 99% pointwise 
confidence intervals (CI) taken at each event time (assessed daily). For each month of age, black 
diamonds show the average hazard of a first redeemed antibiotic prescription (in panel A) and 
the average risk of at least one redeemed antibiotic prescription (in panel B), collapsed across all 
birth-season cohorts. Seasons are winter (December-February), spring (March-May), summer 
(June-August), and autumn (September-November). Shading underneath the x-axis denotes the 
age interval when each birth-season cohort experienced February, the month when the hazard 
peaked (see Figure 3.1A). Boundaries for age intervals by birth-season cohort were defined by 
the 15
th
 of the season’s first month to the 15th of the season’s last month. For example, children 
born in the spring (green, March-May) experienced February from 8.5-11.5 months, because 
children born on May 15 were 8.5 months old on February 1, and children born on March 15 
were 11.5 months old on February 28. 
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Figure 3.4. Segmented trend lines for the interrupted time series analysis of the risk (%) of at 
least one redeemed antibiotic prescription during the first year of life for any antibiotic (black), 
for amoxicillin (red), or for penicillin V (blue), by birth-week cohort, among children born in 
Denmark during 2004-2012. Interruptions are denoted by downward arrows: (1) the near-
coincident Institute for Rational Pharmacotherapy (IRF) bulletin and 7-valent pneumococcal 
conjugate vaccination (PCV7) “catch-up” enrollment schedule; (2) the standard program for 
PCV7 enrollment; (3) the nationwide transition from PCV7 to 13-valent pneumococcal 
conjugate vaccination (PCV13); and (4) the standard program for PCV13 enrollment. Vertical 
lines crossing a segment indicate interruptions in the time series, when potential changes in the 
trend for risk were assessed. Segmented trend lines are adjusted for seasonality using a 
transformed cosine periodic function. For each segment, trend estimates are listed as the change 
in risk (%) per month.  
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CHAPTER 4: ANTIBIOTIC PRESCRIBING DURING INFANCY AND RISK OF 
TREATED OBSTRUCTIVE AIRWAY DISEASES DURING EARLY CHILDHOOD: A 
REGISTRY-BASED NATIONWIDE COHORT STUDY OF CHILDREN BORN IN 
DENMARK, 2004-2012
2
 
 
 
 
4.1.  INTRODUCTION 
Asthma is one of the most common chronic diseases in childhood, and poses a significant 
worldwide burden.
1–3
 Persistent asthma in childhood has also been associated with decreased 
lung function and chronic obstructive pulmonary disease in adulthood.
169
 Childhood asthma 
prevalence ranges 3-7% in Denmark;
4,5
 approximately 10% of all children take prescription 
medication to treat asthma-related symptoms.
6,7
 
Antibiotic prescribing is common in children and is a mainstay of treatment for bacterial 
infections,
32,39
 but overprescribing occurs because not all treated infections are bacterial.
40–43
 
Decreasing unnecessary antibiotic prescribing is central to clinical and public health approaches 
to stifle mounting threats of bacterial resistance.
44–46
 As adequate microbial exposure is 
hypothesized to be important for developing proper immune response in early life
19,26
 and 
antibiotics deplete and disrupt bacterial flora in the gut,
30,31
 they have long been suspected to 
increase the risk of atopic immune response and asthma, particularly in children.
32,14
 Over the 
last two decades, numerous epidemiologic studies have examined the association between 
childhood antibiotic exposure and asthma,
12,14,26,33–37
 yielding conflicting results.
13,38
 
                                               
2
 This chapter will be submitted to the American Journal of Epidemiology. 
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Discrepancies between studies are likely a function of residual confounding by indication or 
other unmeasured factors, reverse causality or recall bias.  
 Our objective was to examine the association between antibiotic exposure during the first 
year of life (henceforth, infancy) and incidence of treated airway diseases during early 
childhood, a proxy for asthma, in Denmark by using a variety of study design and analysis 
strategies to minimize the potential for bias. We estimated 1-, 2-, and 3-year risk differences 
using two distinct but complementary approaches – propensity scores (PS)56,57 and instrumental 
variables (IV).
58–60
 We assessed the dose-response and heterogeneity of antibiotic effects by age, 
and compared results of the population average effect of antibiotic exposure from both 
approaches.
20,170
 
 
 
4.2. METHODS 
The study population for this nationwide cohort study included all children born in 
Denmark from 1 January 2004 to 31 December 2012, identified using the Danish Medical Birth 
Registry (MBR), which contains all live birth records in Denmark since 1973.
151
 We used each 
child’s unique personal registration number (CPR number) to link data across multiple registries, 
including data on their mother, father, and older siblings sharing the same mother. We excluded 
children from the study if (1) the CPR number in MBR for the child, mother, or father could not 
be linked to the Danish Civil Registration System (CRS),
152
 (2) the place of childbirth or 
residence unknown; (3) the child’s sex or date of birth was inconsistent across registries, or (4) 
the child’s date of birth was later than a redeemed prescription record. 
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Data on antibiotic exposure  
To ascertain antibiotic exposure during the first year of life, we used the Danish National 
Health Service Prescription Database (NHSPD) to identify prescriptions for systemic antibiotics 
redeemed in community pharmacies and hospital-based outpatient pharmacies in Denmark,
156
 
and classified each prescription by medication (e.g., amoxicillin, penicillin V) (see Appendix D). 
We calculated age at first redeemed antibiotic prescription, and counted each child’s total 
number of redeemed antibiotic prescriptions during infancy.  
 
Data on treated airway diseases 
The ‘treated airway diseases’ outcome was motivated by our interest in effects on 
clinically relevant asthma-related symptoms, which often occur before children have reached an 
age when asthma can be reliably diagnosed.
170,20
 Follow-up for the outcome started on the 
child’s second birthday, one year after exposure ascertainment ended, to establish exposure-
outcome temporality and reduce potential for reverse causality
26,14
 or unmasking bias.114,117,118 We 
used the NHSPD to identify prescriptions for airway diseases occurring between 2-5 years of age 
(see Appendix D). We grouped them into three drug classes: (1) inhaled β2-adrenoreceptor 
agonists; (2) inhaled glucocorticoids; and (3) leukotriene antagonists. Children were defined as 
having treated airway diseases if they redeemed at least one prescription from at least two (out of 
the three) classes of drugs. Fixed combination treatments could count toward either 
classification, but not both.  
The primary outcome occurrence measures were the risk of treated airway diseases by 
age 3 (1-year risk), age 4 (2-year risk), and age 5 (3-year risk). Due to administrative censoring 
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on 31 Dec 2015, estimates of the 2- and 3-year risk were based only on children born during 
2004-2011 and 2004-2010, respectively.  
     
Data on covariates   
We identified covariates based on previous literature, ascertaining data from the MBR, 
CRS, NHSPD, Danish National Registry of Patients (NPR), and nationwide municipality-level 
census.
171
 Measured covariate constructs included: demographic characteristics; characteristics 
of pregnancy, birth, and the perinatal period; family history of disease and healthcare services 
utilization; and the child’s history of illness during infancy. We used sensitivity analysis to 
assess the influence of controlling for the child’s history of illness during infancy, since timing of 
those covariate measures could occur after antibiotic exposure. See Appendix D for a 
comprehensive description of data sources and administrative codes for all variables used in the 
analysis. 
Out of 86 measured covariates, eight had missing data; 10.5% of children were missing at 
least one covariate value, and 1.2% were missing more than two. We used the expectation-
maximization algorithm to impute maximum likelihood estimates of individual missing values 
for these variables,
172,173
 based on the assumption of missing data at random conditional on the 
joint distribution of those eight variables and 76 other non-collinear numeric variables, including 
antibiotic exposure during infancy and treated airway diseases by age 3.   
  
Propensity score analyses 
Our first series of analyses used propensity score (PS) methods to address measured 
confounding. We examined risk differences for treated airway diseases based on three antibiotic 
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exposure contrasts during infancy: (1) at least one redeemed antibiotic prescription versus none 
(henceforth, ‘any-versus-none’); (2) at least one redeemed amoxicillin prescription versus at least 
one redeemed penicillin V prescription and none for either amoxicillin or amoxicillin clavulanate 
(‘any-amoxicillin’); (3) first redeemed antibiotic prescription of amoxicillin versus penicillin V 
(‘first-antibiotic’), for a head-to-head comparison between the two predominant antibiotics in 
this study population, with differing antibacterial activity.
81
 Separately for each contrast, we 
estimated propensity scores using hierarchically well-formulated
174
 logistic regression models 
containing explanatory terms based on directed acyclic graphs,
175,176
 including potential 
confounding variables,
177
 predictors of treated airway diseases,
177
 higher-order continuous 
terms,
178
 and multiplicative covariate-covariate interaction terms.
178,179,65
  
To estimate 1-, 2-, and 3-year risk differences with 99% confidence intervals (CIs) for 
effects of antibiotic exposure during infancy on treated airway diseases, we specified weighted 
linear binomial models
180
 with robust variance estimators.
181
 To control measured confounding, 
we balanced measured covariate distributions across exposure using weights based on each 
child’s PS and observed exposure. For the ‘any-versus-none’ contrast, we used stabilized 
standardized morbidity ratio (SMR) weights
182–184
 to identify the average treatment effect in the 
treated (ATT). For the ‘any-amoxicillin’ and ‘first-antibiotic’ contrasts, we used stabilized 
inverse-probability-of-treatment (IPT) weights
65,181
 to identify the average treatment effect in the 
population (ATE). To stabilize weights, SMR weights for ‘unexposed’ children were multiplied 
by the inverse of the marginal odds of being exposed; IPT weights for all children were 
multiplied by the prevalence of their observed exposure.
65,181
 We conducted asymmetric 
trimming
63,184,185
 at the 99.99
th
 percentile (for the unexposed) and 0.01
st
 percentiles (for the 
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exposed) of their respective PS distribution to exclude children treated strongly contrary to our 
prediction.  
We assessed the dose-response function using a series of SMR-weighted models to 
estimate the ATT incremental
186
 risk difference for increasing numbers of redeemed antibiotic 
prescriptions during infancy (1 versus 0, 2 versus 1, 3 versus 2, 4 versus 3, and ≥5 versus 4). For 
each distinct contrast in the dose-response analysis except ‘1 versus 0,’ SMR weight models 
included additional explanatory terms for age at first redeemed antibiotic prescription and the 
type of antibiotic prescribed. We also assessed heterogeneity of risk differences by age at first 
redeemed antibiotic prescription, restricted to children who were not admitted to neonatal 
intensive care. We used SMR weights to estimate month-specific ATT risk differences for first 
antibiotic exposure versus remaining exposure-naïve. For further methodological details on PS-
based analyses, see Appendix E.  
 
Instrumental variable analyses 
Despite extensive and granular covariate data, some prominent confounding variables 
remained unmeasured mismeasured. These included paternal smoking, indoor/outdoor air 
pollution, exposure to dust mites, antibiotic prescription indication, and infant feeding practices. 
All multivariable methods, including PS, require an assumption of no unmeasured 
confounding.
59
 When suspected unmeasured confounding might lead to notable bias, 
instrumental variable (IV) approaches might be useful for identifying exposure-outcome 
effects.
59,60,66,187
  
IV analysis is conditional on three assumptions, which in the context of this study are as 
follows: (1) the instrument affects the proportion of children exposed to antibiotics; (2) the 
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instrument is unrelated to other covariates such that the association between the instrument and 
risk of treated airway diseases is not confounded; and (3) the instrument does not directly affect 
the risk of treated airway diseases. Together, these assumptions imply that the instrument can 
only be associated with the risk of treated airway diseases if antibiotic exposure has an effect on 
treated airway diseases.
58,60,68
  
We identified two plausible, distinct calendar time-based instruments to contrast 
otherwise similar birth cohorts, and conducted a separate IV analysis for each. The first analysis 
used a binary instrument defined by season of birth based on seasonal exposure differences 
through 12 months of age, and compared children born in March and April (index) versus 
December and January (referent). Given limited observational data on critical age windows of 
susceptibility, we also conducted exploratory birth-season IV analyses based on exposure 
differences through 9 months (July/August versus December/January) and 6 months of age 
(September versus March).  
The second IV analysis used a binary instrument defined by calendar time of birth,  
comparing birth cohorts from before and after 1 May 2006 that had the largest exposure 
difference
60
 through 12 months of age. This instrument takes advantage of the nationwide rollout 
of the 7-valent pneumococcal conjugate vaccine (PCV7) for children
54,55
 and a nationwide 
bulletin for general practitioners, which provided guidelines for rational antibiotic prescribing in 
children.
47
 The primary calendar-time IV analysis compared children born from 12 March-29 
April 2006 versus 5 March-22 April 2007. All instruments were specified based on analyses of 
antibiotic prescribing during infancy ignoring outcome data.  
We examined all instruments for violation of IV assumptions using information on 
observed antibiotic exposure and measured covariates, falsification tests for changes in data over 
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time, and subject-matter expertise.
60,67,188,189
 Because instruments were not strong enough to be 
scaled to a more precise target population,
60
 we focused IV estimation on the global average 
treatment effect in the population (ATE),
190
 and calculated non-parametric Balke-Pearl
191
 
bounds
59,60
 on the ATE point estimate. We also estimated risk differences with 99% CIs for the 
instrument-outcome association, which corresponds to an intention-to-treat (ITT) estimand in a 
randomized controlled trial with non-compliance.
60
 To minimize residual bias,
59
 we estimated 
weighted
192
 ITT risk differences with robust variance estimators.
181
 In our modelling approach, 
we fit a logistic regression model for the instrument predicted by the covariates, used predicted 
probabilities to generate inverse-probability weights for conditional independence between 
instrument and covariates, and fit a weighted model for the outcome predicted by the instrument. 
For further methodological details on IV-based analyses, see Appendix F.  
All statistical analyses were conducted using SAS software version 9.4 (SAS Institute, 
Inc.; Cary, North Carolina USA). Figures were created using R software version 3.2.1 (R 
Foundation for Statistical Computing; Vienna, Austria) and Inkscape version 0.91 
(www.inkscape.org). This study was approved by the Danish Data Protection Agency (record 
number 2013-41-1790), the Danish Statens Serum Institut (FSEID-00001450), and the 
institutional review board at the University of North Carolina at Chapel Hill (study 13-3155). 
 
 
4.3. RESULTS 
There were 561,729 children born in Denmark during 2004-2012. Before their second 
birthday, 1,214 of those children died, 5,177 emigrated, and 14,002 had missing data on their 
father’s identity. The final study population thus included of 541,336 children, 96.4% of the 
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original birth cohort. Death and emigration were rare during outcome follow-up; after their 
second birthday, 99.2% of children were followed until their fifth birthday.  
Overall, 39.6% of children redeemed at least one antibiotic prescription during the first 
year of life (Table 4.1). The overall risk of treated airway diseases increased from 6.4 per 100 
children at 3 years of age to 10.1 per 100 children by 5 years. Due to large sample size, all 99% 
CI were within 0.1%.   
  
Propensity score analyses 
Table 4.1 reports selected covariate characteristics by level of the ‘any-versus-none’ 
exposure contrast in observed and SMR-weighted data (see Appendix G for extended table with 
additional prominent covariates). In observed data, there was notable covariate imbalance 
between exposed and unexposed children (average standardized absolute mean difference 
(SAMD)
193
 across 83 covariates=0.07, maximum SAMD=0.39). In SMR-weighted data, 
covariate distributions of the unexposed mimicked the covariate distributions of the exposed 
(average SAMD=0.003; maximum SAMD=0.012). Across all PS-based analyses, weighting 
strongly reduced covariate imbalance that existed between exposure groups in observed data 
(Table 4.2). 
In weighted data for the ‘any-versus-none’ contrast, the 1-, 2-, and 3-year risks of treated 
airway diseases among the unexposed were 5.8, 8.1, and 9.3 per 100 children; the 1-, 2-, and 3-
year risk differences for exposure were 3.3 per 100 children (99% CI: 3.0, 3.6), 4.1 (99% CI: 3.8, 
4.4), and 4.5 (99% CI: 4.2, 4.8) (Table 4.3). These estimates suggest an increased risk for treated 
airway diseases among children with at least one redeemed antibiotic prescription during 
infancy, compared to none. SMR-weighting increased the referent risk among the unexposed, 
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resulting in standardized risk difference estimates shifting toward unity compared to the crude. 
There was a dose-response relation between each antibiotic exposure and risk of treated airway 
diseases (Figure 4.1). Inverse-variance weighted
194
 summary estimates suggest that for each 
discrete incremental increase in the number of antibiotic prescriptions redeemed during infancy, 
the standardized 3-year absolute risk of treated airway diseases increased by 2.4 per 100 children 
(99% CI: 2.3, 2.5).  
Among children not admitted to neonatal intensive care (n=492,044), there was some 
evidence of risk difference heterogeneity by age at first antibiotic exposure in SMR-weighted 
data (Figure 4.2). Separately for each age, SMR-weighting balanced covariate distributions 
across exposure groups, subsequently increasing each referent risk. Standardized risk differences 
increased from 1-4 months, then decreased slightly through the middle of the first year of life, 
suggesting marginally worse effects when first exposure to antibiotics occurred between 
approximately 4-7 months. In a sensitivity analysis that omitted control of covariates measured 
during infancy (e.g., diagnosed infections, visits to pediatrician), risk differences were higher 
than in the primary analysis, and decreased more markedly from 4-10 months of age (see 
Appendix H). Covariate imbalance was highest in the first month of life (Table 4.2), suggesting 
relatively higher residual bias potential in that month for primary and sensitivity analyses.  
Compared to the ‘any-versus-none’ exposure contrast, there was less covariate imbalance 
in observed data for the ‘any-amoxicillin’ and ‘first-antibiotic’ contrasts; imbalances were 
further diminished in IPT-weighted data (Table 4.2; see detailed tables in Appendix G). In IPT-
weighted data, compared to children with at least one redeemed penicillin V prescription during 
infancy (but none for amoxicillin), children with at least one redeemed amoxicillin prescription 
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had increased risk of treated airway diseases; there was little evidence of differential risk by type 
of first antibiotic prescription (Table 4.3).  
  
Instrumental variable analyses 
Instruments for birth-season and calendar-time were strong determinants of antibiotic 
exposure during infancy (Table 4.4). In observed data for all instruments, there was minimal 
covariate imbalance across levels of the instrument, which was further improved by weighting 
(Table 4.2). Despite these characteristics, all of these instruments were too weak to identify 
causal effects, as exemplified by extreme Balke-Pearl bounds (Table 4.3). Further, an 
exploratory analysis demonstrated high potential for bias and limited precision of local average 
treatment effect
58,68
  estimates based on these instruments (see Appendix I). Weighted ITT 
estimates did not provide consistent evidence of a causal effect (Table 4.3) and all 99% CIs 
included unity. Point estimates for birth-season instruments based on exposure differences at 12 
and 9 months of age suggested decreased risk of treated airway diseases in populations with 
higher antibiotic exposure, whereas the 6-month birth-season instrument suggested increased 
risk. In a sensitivity analysis of the calendar-time instrument (Figure 4.3), to enhance instrument 
strength, we trimmed two birth-week cohorts from the interior of the birth interval of each 
instrument level (see Table 4.4). This resulted in weighted ITT estimates that were suggestive of 
a null instrument-outcome relation (Table 4.3).   
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4.4. DISCUSSION 
In this nationwide cohort study of children born during 2004-2012 in Denmark, we found 
evidence based on propensity score methods that antibiotic exposure during infancy was 
associated with increased risk of treated airway diseases from 2-5 years of age. We observed a 
dose-response relation and evidence suggesting minor heterogeneity of exposure effects by the 
age at which the first redeemed antibiotic prescription occurred. Head-to-head comparisons of 
antibiotics demonstrated small, if any, increased risk for exposure to amoxicillin versus penicillin 
V, which cast some doubt on a causal effect of antibiotics on treated airway diseases, since 
amoxicillin targets a broader range
81
 of bacteria than penicillin V. Unfortunately, the instruments 
identified for this study were of marginal strength, limiting inference regarding the potential 
causal relation. Nevertheless, these results also cast some doubt on the presence of a causal effect 
in this setting.  
Results from our propensity score analyses corroborate recent findings
7,26,36,37
 suggesting 
that antibiotic exposure in infancy would increase the risk of airway diseases later in life; 
however, despite being imprecise, the results from our instrumental variable analysis shed some 
doubt
35,108
 on the causality of the observed association.
14,33,34
 Assuming there is an effect, we 
provide new information on discrete dose-response relations and risk difference heterogeneity by 
age at first exposure, as well as a head-to-head comparison indicating negligible difference in 
risk between exposure to amoxicillin versus penicillin V. 
A prominent difference across studies of antibiotics and airway diseases is the outcome 
definition,
34
 in part because valid and meaningful measures are difficult to ascertain.
195
 Criteria 
often include asthma diagnosis, medication use, or parental report. The criterion of medication 
use (alone) has been criticized as an identifier of event occurrence because it does not include 
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information on asthma diagnosis,
196
 yet is widely used.
5,6,195,197,198
 Although children under 5 
years of age often experience remission of symptoms,
20
 airway exacerbations that necessitate 
treatment pose a serious burden to quality of life for children and their families, and may be a 
harbinger of chronic conditions like asthma. Furthermore, because general practitioners in 
Denmark treat most exacerbations but are not mandated to record a diagnosis, the sensitivity 
(i.e., the proportion of children with airway diseases recognized as such) of our treatment-based 
outcome definition would be higher than if we had also required a diagnosis code. Higher 
sensitivity renders the treatment-based outcome definition more optimal for risk difference 
estimation.
119
 
Prior studies offer contradictory evidence of a dose-response relation,
12,14,26,33–37
 each one 
basing inference on a multivariable linear model with categorical or continuous exposure coding. 
Results from our analysis suggest a deleterious dose-response relation, but are based on a 
different approach – a series of disjoint models, each one weighted to minimize confounding for 
that discrete exposure increase. Our approach minimizes potential violation of positivity and 
exchangeability assumptions,
65,199
 and focuses on an estimator that is tied to the clinical decision 
to prescribe one more antibiotic regimen to a child, or not. These results are subject to potential 
residual confounding bias similar to the overall ‘any-versus-none’ exposure contrast. 
Three other studies
35–37
 have attempted to handle confounding by indication by 
comparing antibiotics that are classically prescribed for different indications; those studies have 
found evidence of smaller effects for antibiotics used for skin and urinary infections compared to 
antibiotics used for respiratory infections. In our analysis of the ‘first-antibiotic’ contrast, we 
attempted to address this potential residual bias by comparing antibiotics that are prescribed for 
similar indications but have different potency. Using an active comparator effectively restricted 
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the population – based on indication – to children who redeemed a prescription for one of two 
antibiotics that tend to be prescribed for a similar reason.
184
 According to the hygiene 
hypothesis,
19,25,26
 we expected to observe increased risk of treated airway diseases among 
children first exposed to amoxicillin versus penicillin V
26,75,92
 because amoxicillin has a broader 
spectrum of antibacterial activity.
81
 Our findings did not suggest an effect of antibiotic subtype 
on risk, casting doubt on causality.   
Family history of immune dysfunction as well as other genetic and environmental 
characteristics that cluster within the family unit are primary causes of asthma.
26,14,36,20
 They are 
important confounding factors in this setting since they likely impact healthcare seeking 
behaviors and probability of redeeming antibiotic prescriptions. Subsequently, along with many 
other covariates, our study controlled for the parent and older sibling history of obstructive 
airway diseases, irritable bowel disease, and antibiotic prescriptions; parent and child history of 
doctor visits; maternal smoking; birth order; and other demographic characteristics. A recent 
study
36
 controlled for family characteristics by matching asthmatic children with their non-
asthmatic siblings, and also found evidence of increased risk for asthma after 2 years of age. 
 
Strengths and limitations 
This study has several strengths. To our knowledge, it is the largest study conducted to 
date concerning early life antibiotic exposure and airway diseases in childhood. The registry 
databases facilitated our implementation of this nationwide cohort study of all children born in 
Denmark over a nine-year period. The registries that we linked contain accurate data on the date 
and medication type of redeemed prescriptions, date of birth, residence, data on healthcare 
utilization, and other variables in this study.
80,152,153,156
 The tax-supported healthcare system for 
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the entire Danish population includes free access to healthcare and partial reimbursement of 
prescribed medications,
25
 leading to minimal disparity in access to healthcare services in our 
study population.  
This is the first study on antibiotics and childhood airway diseases to use propensity 
scores for controlling measured confounding. In addition to the large study size, propensity 
scores allowed for more extensive covariate control than prior studies by shifting the burden for 
model convergence from the treated airway diseases variable onto the antibiotic exposure 
variable, thus accommodating a larger conditioning set of covariates.
180
 Key covariates measured 
in this study include several that had not been jointly assessed in prior studies, including: 
parent/older-sibling history of asthma or other obstructive airway diseases; parent/older-sibling 
history of redeeming antibiotic prescriptions; a granular variable for maternal smoking status; 
parent/infant history of visits to various clinical specialists; maternal redemption of antibiotic, 
corticosteroid, and acid-suppressive prescriptions during pregnancy; pregnancy and birth 
complications; cesarean versus vaginal delivery; birth order; gestational age at birth; birth 
weight; parental immigrant status; geographic location of child’s residence; time-varying 
population-level pneumococcal vaccination coverage; admission and treatments in neonatal 
intensive care; and diagnosis during infancy of congenital malformation. As a result of using 
propensity scores, the ATT/ATE estimands specified in our analyses promote clear inference 
regarding hypothetical exposure interventions which might have clinical or policy relevance at 
the population level.  
This is also the first study on this topic to use instrumental variables to address 
confounding bias, which threatens validity of all studies on this topic that rely on measured 
confounding control. Because available data were lacking information on some key potential 
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confounding variables, we addressed the possibility of residual unmeasured confounding by 
using instrumental variable analyses which do not require an assumption of no unmeasured 
confounding. The findings from our instrumental variable analysis were hampered by weak 
instruments but nevertheless cast some doubt on causality. 
This study also has some important limitations. We lacked data on indication since most 
antibiotics prescribed to infants are administered by general practitioners who are not mandated 
to record a diagnosis to issue prescriptions.
39
 This limited our ability to control confounding by 
indication, but we controlled for children’s hospital-diagnosed infection history and their 
frequency of doctor visits during infancy. Two prior studies
35,36
 used antibiotic subtype to assess 
confounding by indication; however, we were precluded from adopting this approach because 
90% of antibiotic prescriptions in our study population were for amoxicillin or penicillin V.  
The NHSPD lacks information on medication use.
156,200
 Our interpretation of data implies 
a correlation between filling a prescription and subsequently taking the drug as prescribed, which 
could result in exposure misclassification. This would not affect our outcome, however, because 
obtaining medication to treat one’s child’s respiratory symptoms is in itself meaningful, 
irrespective of whether the child actually used the medication or not. There are myriad potential 
definitions that could be used to identify outcomes of interest in this context, and we 
purposefully selected the outcome of treated airway diseases because it is a common, serious 
condition in early childhood. Further, in an analysis of data on children with follow-up data 
through 7 years of age, we observed that treated airway diseases by age 5 were predictive of 
asthma and treatment of related symptoms at age 7 (see Appendix J). Children classified with 
treated airway diseases by age 5 accounted for approximately 75% of children with asthma at 
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age 7, and 30% still received treatment for exacerbations at age 7.  There was also agreement of 
treated airway diseases classification across discrete years of age from 2-5 (see Appendix K). 
Besides age at first exposure, specifying other sources of potential effect heterogeneity 
(e.g., sex, birth order, family history of asthma) was beyond the scope of this article. Even in the 
presence of effect heterogeneity, however, propensity score-based approaches estimate valid 
marginal exposure effects
183,184
 (i.e., the ATT and ATE).  Thus, our study is useful for 
interpreting population average effects in Denmark, but some subgroup-specific effects remain in 
question.   
The instruments identified for this analysis were not strong enough for identifying a 
meaningful causal estimate. The ITT estimator does not provide optimal inference since it is 
likely biased toward the null
60
 compared to estimates of exposure-outcome effects; however, the 
ITT estimate still addresses potential exposure effects in the total population of children. Given 
that it is unlikely that other population-based data sources would provide substantially better 
covariate information to obtain covariate-controlled effect estimates, investigators should aim to 
identify stronger instruments or other quasi-experimental applications that could identify 
sufficiently precise causal estimates.   
 
Conclusions 
 Despite extensive covariate data to control confounding bias in this nationwide cohort 
study of children born in Denmark during 2004-2012, our propensity score analysis still indicates 
that antibiotic exposure during infancy is associated with increased risk of treated airway 
diseases from 2-5 years of age. Two analyses addressing unmeasured and residual confounding 
(active comparator, IV) showed no association, however, thus increasing doubts about a causal 
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interpretation. Future research should focus on identifying settings where stronger instrumental 
variables are available.  
In light of inconclusive evidence in this study and in the published literature to date,  
antibiotic exposure during early life may or may not cause asthma or other related respiratory 
dysfunction in later childhood. Even if there is no true causal relation, the overall public health 
message concerning unnecessary antibiotic use shall remain unchanged. Particularly in children, 
rational antibiotic prescribing is achievable
48–50
 and critical for minimizing unnecessary side 
effects at the individual level, healthcare expenditures for acute clinical consultation,
32
 and 
bacterial resistance at the population level. 
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Table 4.1. Selected characteristics of infants born in Denmark during 2004-2012, by level of 
antibiotic exposure during the first year of life (‘any-versus-none’) in observed data and 
stabilized standardized morbidity ratio (SMR) weighted data; N=541,336. 
 
  
Observed data 
 
Weighted data 
  
Exposed Unexposed 
  
Unexposed 
 
  
n = 214,256 n = 327,080 
  
mw = 1.005 
 
 
  % % SMD 
 
% SMD 
Male sex 
 
55.8 48.2 0.15 
 
55.9 0.00 
Birth order (mother's live births only) 
   
0.17 
  
0.01 
First-born 
 
39.4 47.7 
  
39.1 
 
Second 
 
41.1 34.8 
  
41.4 
 
Third 
 
14.8 13.4 
  
14.9 
 
Fourth 
 
3.5 3.0 
  
3.4 
 
Fifth or higher 
 
1.3 1.0 
  
1.2 
 
Year of birth 
   
0.07 
  
0.01 
2004-2006 
 
36.4 33.2 
  
36.8 
 
2007-2009 
 
33.8 34.2 
  
33.7 
 
2010-2012 
 
29.8 32.5 
  
29.5 
 
Season of birth 
   
0.16 
  
0.01 
Winter (Dec, Jan, Feb) 
 
23.5 23.3 
  
23.8 
 
Spring (Mar, Apr, May) 
 
28.5 22.8 
  
28.4 
 
Summer (Jun, Jul, Aug) 
 
26.6 26.9 
  
26.3 
 
Autumn (Sep, Oct, Nov) 
 
21.4 27.0 
  
21.4 
 Population density of municipality of residence at 
birth, residents per km
2
 (median, IQR) 
 
(161, 85-744) (177, 87-794) -0.08 
 
(161, 85-744) 0.00 
Older siblings, combined rate of antibiotic 
prescription*† 
   
0.39 
  
0.01 
0 
 
43.3 54.3 
  
42.9 
 
>0-1 
 
20.7 25.7 
  
20.8 
 
>1-2 
 
18.0 12.6 
  
18.2 
 
>2 
 
18.0 7.3 
  
18.1 
 Any older family member redeemed ≥1 prescription 
for obstructive airway disease* 
 
37.8 29.9 0.17 
 
37.9 -0.01 
Diagnosis of otitis media* 
 
2.4 0.2 0.19 
 
2.2 0.00 
Diagnosis of bronchitis, bronchiolitis, RSV 
pneumonia* 
 
5.1 2.0 0.16 
 
5.1 -0.01 
Infant, no. admissions to pediatrician* 
   
0.27 
  
0.01 
0 
 
69.1 80.1 
  
69.0 
 
1 
 
16.6 12.7 
  
16.7 
 
≥2 
 
14.3 7.2 
  
14.2 
 Maternal smoking during pregnancy‡ 
   
0.09 
  
0.00 
Did not smoke 
 
84.5 87.5 
  
84.4 
 Stopped smoking during pregnancy 
 
2.6 2.4 
  
2.6 
 Smoking during pregnancy 
 
12.9 10.1 
  
13.0 
  
SMD = standardized mean difference (mean difference ÷ pooled standard error)  
mw = mean weight   
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IQR = interquartile range           
RSV = respiratory syncytial virus          
* Ascertained until the child's first birthday.  
† Rate = number of prescriptions ÷ person-years of follow-up until the child's first birthday; 
extreme rates of medication use were imputed with the 99.9th percentile value from their rate-
specific distribution. 
‡ Ascertained during the 245 days preceding the child's date of birth. 
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Table 4.2. Summary measures of covariate imbalance in observed and weighted data based on 
the average standardized absolute mean difference (SAMD), comparing across levels of 
antibiotic exposure in propensity score (PS)-based analyses, and comparing across levels of the 
instrument in instrumental variable analyses. 
 
  Average SAMD 
  Observed data Weighted data 
PS contrast: Any-versus-none 
  Overall analysis 0.07 0.003 
Dose-response analysis 
  1 versus 0 0.05 0.002 
2 versus 1 0.03 0.002 
3 versus 2 0.03 0.002 
4 versus 3 0.02 0.003 
≥5 versus 4 0.05 0.004 
Age at first exposure* 
  1st month versus later/never 0.07 0.013, 0.011† 
2nd month versus later/never 0.11 0.003, 0.003† 
3rd month versus later/never 0.11 0.011, 0.003† 
4th month versus later/never 0.11 0.008, 0.003† 
5th month versus later/never 0.10 0.003, 0.002† 
6th month versus later/never 0.09 0.002, 0.002† 
7th month versus later/never 0.08 0.002, 0.001† 
8th month versus later/never 0.07 0.001, 0.001† 
9th month versus later/never 0.06 0.001, 0.001† 
10th month versus later/never 0.05 0.001, 0.001† 
11th month versus later/never 0.05 0.002, 0.002† 
12th month versus later/never 0.05 0.001, 0.001† 
PS contrast: Any-amoxicillin 0.03 0.003 
PS contrast: First-antibiotic 0.02 0.002 
Instrumental variables 
  Birth-season, 12 months‡ 0.02 0.001 
Birth-season, 9 months§ 0.02 0.001 
Birth-season, 6 monthsǁ 0.02 0.002 
Calendar-time, primary¶ 0.03 0.003 
Calendar-time, enhanced** 0.03 0.003 
 
SAMD = standardized absolute mean difference (absolute value of the quotient for the mean 
difference divided by pooled standard error) 
PS = propensity scores 
*  Restricted to children who were never admitted to neonatal intensive care. 
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†  The second value represents the SAMD summary measure from sensitivity analysis, and is 
based on the revised set of conditioning covariates for that analysis, which do not include 
characteristics measured during infancy. 
‡  Instrument regarding exposure differences at 12 months, comparing children born in March 
and April versus December and January 
§  Instrument regarding exposure differences at 9 months, comparing children born in July and 
August versus December and January 
‖ Instrument regarding exposure differences at 6 months, comparing children born in September 
versus March 
¶ Instrument regarding exposure differences at 12 months, comparing children born during 12 
March-29 April 2006 versus 5 March-22 April 2007 
** Instrument regarding exposure differences at 12 months, comparing children born during 
(12/3/2006-18/3/2006, 26/3/2006-1/4/2006, 9/4/2006-29/4/2006) versus (5/3/2007-18/3/2007, 
26/3/2007-1/4/2007, 9/4/2007-22/4/2007) 
 
 
  
Table 4.3. Summary of results across all propensity score and instrumental variable analyses for the relation between antibiotic 
exposure during the first year of life and treated airway disease, among children born in Denmark 2004-2012. 
 
  1-year risk difference (by age 3)   2-year risk difference (by age 4) 
  
3-year risk difference (by age 5) 
  
Referent 
risk RD* 99% CI NNTH RR   
Referent 
risk RD* 99% CI NNTH RR 
  
Referent 
risk RD* 99% CI NNTH RR 
Propensity scores 
           
 
     Any-versus-none contrast† 
           
 
     Crude 4.5 4.7 4.5, 4.8 21 2.0 
 
6.4 5.8 5.6, 6.1 17 1.9 
 
7.5 6.4 6.1, 6.6 16 1.9 
SMR-weighted for ATT 5.8 3.3 3.0, 3.6 30 1.6 
 
8.1 4.1 3.8, 4.4 24 1.5 
 
9.3 4.5 4.2, 4.8 22 1.5 
Any-amoxicillin contrast‡ 
           
 
     Crude 8.2 1.4 1.1, 1.8 71 1.2 
 
11.0 1.8 1.4, 2.2 56 1.2 
 
12.6 2.0 1.5, 2.4 51 1.2 
IPT-weighted for ATE 8.4 1.1 0.7, 1.5 91 1.1 
 
11.3 1.3 0.9, 1.8 75 1.1 
 
12.8 1.5 1.0, 2.0 66 1.1 
First-antibiotic contrast§ 
           
 
     Crude 9.3 -0.3 -0.6, 0.0 -327 1.0 
 
12.3 -0.3 -0.7, 0.1 -312 1.0 
 
14.0 -0.4 -0.9, 0.0 -249 1.0 
IPT-weighted for ATE 9.1 -0.1 -0.4, 0.3 -1302 1.0 
 
12.2 -0.1 -0.5, 0.3 -1222 1.0 
 
13.8 -0.1 -0.6, 0.3 -792 1.0 
Instrumental variables 
           
 
     Birth-season, 12 months‖ 
           
 
     Balke-Pearl bounds for ATE 
 
-69, 77 
 
-1.4, 1.3 
   
-69, 77 
 
-1.4, 1.3 
 
 
 
-70, 77 
 
-1.4, 1.3 
 Weighted ITT 6.5 -0.2 -0.5, 0.1 -567 1.0 
 
9.0 -0.4 -0.7, 0.0 -275 1.0 
 
10.3 -0.5 -0.9, 0.0 -217 1.0 
Birth-season, 9 months¶ 
           
 
     Balke-Pearl bounds for ATE 
 
-61, 85 
 
-1.6, 1.2 
   
-62, 84 
 
-1.6, 1.2 
 
 
 
-62, 84 
 
-1.6, 1.2 
 Weighted ITT 6.6 -0.3 -0.6, 0.0 -385 1.0 
 
9.0 -0.3 -0.7, 0.1 -338 1.0 
 
10.4 -0.3 -0.7, 0.1 -371 1.0 
Birth-season, 6 months** 
           
 
     Balke-Pearl bounds for ATE 
 
-56, 92 
 
-1.8, 1.1 
   
-57, 91 
 
-1.8, 1.1 
 
 
 
-57, 90 
 
-1.8, 1.1 
 Weighted ITT 6.3 0.3 -0.1, 0.8 296 1.1 
 
8.6 0.2 -0.3, 0.7 469 1.0 
 
9.8 0.4 -0.1, 1.0 226 1.0 
Calendar-time, primary†† 
           
 
     Balke-Pearl bounds for ATE 
 
-72, 76 
 
-1.4, 1.3 
   
-71, 76 
 
-1.4, 1.3 
 
 
 
-71, 76 
 
-1.4, 1.3 
 Weighted ITT 6.2 0.0 -1.0, 1.0 6849 1.0 
 
8.4 -0.3 -1.4, 0.9 -388 1.0 
 
9.5 -0.3 -1.5, 1.0 -385 1.0 
Calendar-time, enhanced‡‡  
           
 
     Balke-Pearl bounds for ATE 
 
-71, 76 
 
-1.4, 1.3 
   
-71, 76 
 
-1.4, 1.3 
 
 
 
-71, 76 
 
-1.4, 1.3 
 Weighted ITT 6.2 0.2 -1.0, 1.5 467 1.0   8.3 0.0 -1.4, 1.4 4878 1.0 
  
9.4 0.1 -1.4, 1.6 858 1.0 
 
Abbreviations and footnotes on following page. 
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RD = risk difference point estimate 
CI = confidence interval 
NNTH = number needed to treat to harm (1÷RD) 
RR = risk ratio point estimate 
SMR = standardized morbidity ratio 
ATT = average treatment effect in the index treatment subgroup 
IPT = inverse-probability-of-treatment 
ATE = average treatment effect in the population 
ITT = intention-to-treat 
* Risk difference per 100 children 
† Exposure contrast between children who redeemed at least one antibiotic prescription during infancy versus none  
‡ Exposure contrast between children who during their infancy redeemed at least one amoxicillin prescription versus at least one 
penicillin V prescription and none for either amoxicillin or amoxicillin clavulanate  
§ Exposure contrast between children whose first redeemed antibiotic prescription during infancy was for amoxicillin versus 
penicillin V  
‖ Instrument regarding exposure differences at 12 months, comparing children born in March and April versus December and 
January 
¶  Instrument regarding exposure differences at 9 months, comparing children born in July and August versus December and January 
** Instrument regarding exposure differences at 6 months, comparing children born in September versus March 
†† Instrument regarding exposure differences at 12 months, comparing children born during 12 March-29 April 2006 versus 5 March-
22 April 2007 
‡‡ Instrument regarding exposure differences at 12 months, comparing children born during (12/3/2006-18/3/2006, 26/3/2006-
1/4/2006, 9/4/2006-29/4/2006) versus (5/3/2007-18/3/2007, 26/3/2007-1/4/2007, 9/4/2007-22/4/2007)
7
2
 
73 
 
Table 4.4. Strength of instruments related to antibiotic exposure 
 
Instrument RD* (99% CI) F statistic Partial r
2
         
Birth-season, 12 months† 7.0 (6.4, 7.6) 951 0.005 
       
Birth-season, 9 months‡ 9.4 (8.9, 9.9) 2546 0.013 
       
Birth-season, 6 months§ 6.2 (5.8, 6.7) 1165 0.013 
       
Calendar-time, primary‖ 4.6 (2.5, 6.6) 37 0.002 
       
Calendar-time, enhanced¶ 6.2 (3.8, 8.6) 49 0.003 
       
 
RD = risk difference           
CI = confidence interval           
* Risk difference per 100 children for the relation between the instrument and redeeming at least 
one antibiotic prescription during infancy.       
† Instrument regarding exposure differences at 12 months, comparing children born in March 
and April versus December and January. 
‡ Instrument regarding exposure differences at 9 months, comparing children born in July and 
August versus December and January. 
§ Instrument regarding exposure differences at 6 months, comparing children born in September 
versus March. 
‖ Instrument regarding exposure differences at 12 months, comparing children born during 12 
March-29 April 2006 versus 5 March-22 April 2007. 
¶ Instrument regarding exposure differences at 12 months, comparing children born during 
(12/3/2006-18/3/2006, 26/3/2006-1/4/2006, 9/4/2006-29/4/2006) versus (5/3/2007-18/3/2007, 
26/3/2007-1/4/2007, 9/4/2007-22/4/2007).
  
Figure 4.1. Dose-response relations in standardized morbidity ratio (SMR)-weighted data for increasing antibiotic exposure and risk of 
treated airway diseases among children born in Denmark, 2004-2012. For 1-year (Panel A), 2-year (Panel B), and 3-year (Panel C) 
follow-up periods for treated airway diseases, risks and risk differences per 100 children are plotted against incremental increases in 
the number of redeemed antibiotic prescriptions during infancy, with robust 99% confidence intervals (CI). For each contrast, SMR-
weighted data represent children remaining in the analysis after asymmetric trimming at the 99.99th percentile (for the referent 
exposure group) and 0.01st percentiles (for the index exposure group) of the contrast-specific propensity score distribution. Darkened 
squares represent risks among index exposure group, whitened squares represent the risk among the referent exposure group, and 
vertical whiskers represent 99% CIs for risk estimates. In settings with overlapping data on risks, point estimates and 99% CIs were 
horizontally jittered. Risk differences can be seen as the difference between the index and referent risks for each comparison; 
additionally, risk differences are plotted using black segments to connect point estimates and gray shading to denote pointwise robust 
99% CIs for risk differences. For each follow-up interval (i.e., 1-year, 2-year, or 3-year), the inverse-variance weighted summary 
estimate is listed for the incremental risk difference per 100 children. The dose-response is indicated by the persistent increased risk of 
treated airway disease for each index exposure versus its referent, across the series of discrete incremental increases in redeemed 
antibiotic prescriptions during infancy. 
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Figure 4.2. Risk difference heterogeneity by age at first redeemed antibiotic prescription for the relation between antibiotic exposure 
and risk of treated airway diseases among children born in Denmark, 2004-2012, who were never admitted to neonatal intensive care. 
For 1-year (Panel A), 2-year (Panel B), and 3-year (Panel C) follow-up periods for treated airway diseases, risks for (newly exposed 
and exposure-naïve children) and risk differences per 100 children are plotted with robust 99% confidence intervals (CI), stratified by 
age (in months) at which each antibiotic exposure contrast was drawn. For each age-specific contrast, SMR-weighted data represent 
children who did not redeem an antibiotic prescription prior to the month of age in question, and who remained in the analysis after 
asymmetric trimming at the 99.99th percentile (for the referent exposure group) and 0.01st percentiles (for the index exposure group) 
of the age-specific propensity score distribution. Darkened squares represent risks among the newly exposed group, whitened squares 
represent the risk among the exposure-naïve group, and vertical whiskers represent 99% CIs for risk estimates. In settings with 
overlapping data on risks, point estimates and 99% CIs were horizontally jittered. Risk differences can be seen as the difference 
between the index and referent risks for each comparison; additionally, risk differences are plotted using black segments to connect 
point estimates and gray shading to denote pointwise robust 99% CIs for risk differences. 
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Figure 4.3. Birth cohort differences in the risk of redeeming at least one antibiotic prescription 
during the first year of life, among children born in Denmark during 2005-2007 (N=185,164). 
The calendar-time instrument was based on two population-level differences between children 
born in Denmark before versus after 1 May 2006, which have plausible links to differences in 
antibiotic use. First, children born after 1 May 2006 were eligible for the Danish childhood 
vaccination program’s 7-valent pneumococcal conjugate vaccine (PCV7);54,55 children born from 
1 November 2006 to 30 June 2007 were enrolled in a three-dose catch-up PCV7 program that 
had coverage of 71% for the first dose, 67% for the second, and 55% for the third.
54
 Second, for 
children born between 1 May 2006 and 1 May 2007, a nationwide bulletin regarding rational 
antibiotic use was published during their infancy (in April 2007) by the Danish Health and 
Medicine Authority’s Institute for Rational Pharmacotherapy (IRF), a government institute.47 To 
establish conditional independence between the calendar-time instrument and birth-season – and 
thus reduce potential violation of IV assumptions 2 or 3 – we restricted the calendar-time IV 
analysis to a comparison of children born in the same season. (Gray shading indicates excluded 
birth cohorts from the calendar-time instrumental variable analysis. We also limited the time 
period between
60
 the birth-season instrument levels to one year. 
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CHAPTER 5: DISCUSSION 
 
 
5.1. SUMMARY OF FINDINGS 
The primary objectives for the first specific aim were to estimate birth-month and birth-
season cohort effects on antibiotic prescribing during infancy in Denmark, and to examine the 
potential impacts of the IRF bulletin and the PCV7 and PCV13 vaccination programs on 
population-level antibiotic prescribing trends across birth cohorts over time. We observed that 
the proportion of infants born in Denmark who received antibiotics during their first year of life 
decreased over time, and that the total number of antibiotic prescriptions per infant-year also 
decreased. Yet, over time, those infants who received antibiotic prescriptions received increasing 
numbers of prescriptions and days supplied, resulting in little change over time in population-
level antibiotic burden. Amoxicillin, a broad-spectrum antibiotic, became increasingly prominent 
over time, while penicillin V prescribing decreased each year after 2005. In our analysis of time 
to first redeemed antibiotic prescription, we observed that the association between birth-season 
and risk of redeeming an antibiotic prescription varied with increasing age. In our interrupted 
time series analysis, we found that risk of at least one redeemed amoxicillin prescription during 
infancy decreased after the IRF bulletin and the PCV7 “catch-up” program, and after PCV13 
program initiation. 
The primary objective for the second specific aim was to examine the association 
between antibiotic exposure during infancy and incidence of treated airway diseases during early 
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childhood in Denmark. We found evidence based on propensity score methods that antibiotic 
exposure during infancy was associated with increased risk of treated airway diseases from 2-5 
years of age, as well as a dose-response relation and evidence suggesting minor heterogeneity of 
exposure effects by the age at which the first redeemed antibiotic prescription occurred. Head-to-
head comparisons of antibiotics, however, demonstrated small, if any, increased risk for 
exposure to amoxicillin versus penicillin V, casting doubt on a causal effect. Unfortunately, the 
instruments identified for this study were of marginal strength, limiting inference regarding the 
potential causal relation.  
 
5.2. PUBLIC HEALTH IMPLICATIONS 
For the first specific aim, our analysis used detailed individual-level nationwide data on 
antibiotic prescribing to provide new information on risk and time to first redeemed antibiotic 
prescription, which are important estimators for public health. The findings regarding birth-
season cohort effects may inform two aspects of future pediatric studies examining antibiotics as 
the exposure of interest. First, there may be inherent differences in antibiotic exposure patterns 
during early life that are determined in part by season of birth. Second, because of potential 
differences in vulnerability to both short- and long-term effects of microbial insults in early life 
based on age at first antibiotic use,
24,168
 birth-season differences – which are associated with age 
at first antibiotic use – may modify the effects of antibiotic exposure on various outcomes. 
Investigators of antibiotic exposure effects should consider these cohort effects when assessing 
effect modification or confounding. 
 This is the first study to date to explicitly evaluate the impact of the IRF bulletin (in 
2007) and pneumococcal conjugate vaccines (from 2007 onward) on antibiotic prescribing 
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patterns in the infant population of Denmark. This study demonstrated that amoxicillin 
prescribing decreased after the IRF bulletin and the PCV7 “catch-up” program, and after PCV13 
program initiation, building on prior studies of antibiotic prescribing in early 
childhood.
50,99,139,146–149
 Future studies of antibiotic safety and effectiveness in children that span 
multiple birth-season or birth-year cohorts should take into account similar birth cohort effects 
that may apply to their study setting, since they highlight fundamental differences in antibiotic 
use that may render some subgroups more susceptible to adverse effects than other subgroups. 
In our assessment of the association between antibiotic prescribing and treated airway 
diseases, propensity score analyses yielded results which aligned with recent evidence
7,26,36,37
 
suggestive of increased risk of airway diseases later in life following antibiotic exposure during 
infancy. Assuming there is an effect, we provide new information on discrete dose-response 
relations and risk difference heterogeneity by age at first exposure. Despite being imprecise, the 
results from our instrumental variable analysis shed some doubt
35,108
 on the causality of the 
observed association.
14,33,34
 We also provide new information on a head-to-head comparison of 
amoxicillin and penicillin V, which also cast doubt on a causal relation, since amoxicillin 
exposure was not associated with increased risk of treated airway diseases despite its broader 
range of antibacterial activity. Our study focused on the adverse outcome of treated airway 
diseases, which is a relevant outcome for the clinical and public health setting. Although children 
under 5 years of age often experience remission of symptoms,
20
 airway exacerbations that 
necessitate treatment pose a serious burden to quality of life for children and their families, and 
may signal chronic conditions like asthma. The symptoms associated with the treated airway 
diseases outcome are of grave importance in the short-term, and also carry potential to impact 
long-term health. 
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5.3.  FUTURE RESEARCH 
Our propensity score analysis provides evidence suggesting that antibiotic exposure 
during infancy is associated with increased risk of treated airway diseases from 2-5 years of age, 
but the head-to-head comparison between amoxicillin and penicillin V casts some doubt on a 
causal relation. Future research could explore other sources of heterogeneity of the effect of 
antibiotic exposure on obstructive airway diseases. Other potentially meaningful factors to 
examine include being of a multiple birth (e.g., twins, triplets), sex, calendar time of birth, family 
history of asthma and airway diseases, birth order, gestational age at birth, neonatal immune 
susceptibility/dysfunction, individual pneumococcal vaccination receipt, and exposure to 
smoking and air pollution in the home. Similarly, future studies could examine comparisons of 
heterogeneous antibiotic treatment patterns to disentangle the competing effects of age at 
antibiotic exposure and overall burden of antibiotic exposure on the incidence of childhood 
asthma and treated airway diseases.  
Further clarification of the relation between early life antibiotic exposure and risk of 
asthma or other obstructive airway diseases is needed, using quasi-experimental analytic 
methods to identify hypothetical intervention effects in well-defined target populations. In 
particular, an innovative step toward more conclusive inference could stem from a stronger 
instrumental variable analysis than ours.  
 
5.4. CONCLUSIONS 
Season of birth impacted children’s overall 1-year risk of redeeming at least one 
antibiotic prescription during infancy as well as the age at which their first redeemed antibiotic 
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prescription occurred. Although penicillin V prescribing declined steadily during 2004-2012, 
amoxicillin prescribing was dynamic over the study period, decreasing after a bulletin on rational 
antibiotic use was distributed to general practitioners and two nationwide pneumococcal 
vaccination programs were rolled out. Birth-season and birth-year cohort effects may be 
important for assessing effect modification or confounding, and should be considered in future 
investigations of safety and effectiveness of antibiotic exposures in children. 
 Our propensity score analysis, despite using extensive covariate data to control 
confounding, still indicates that antibiotic exposure during infancy is associated with increased 
risk of treated airway diseases from 2-5 years of age among children born in Denmark during 
2004-2012. Analyses that used an active comparator exposure contrast and instrumental 
variables to address unmeasured and residual confounding showed little evidence of a causal 
association. Future research should target the identification of stronger instrumental variables to 
assess the potential causal association between antibiotic exposure in early life and incidence of 
obstructive airway diseases. 
Exposure to antibiotic medication during early life may or may not cause asthma or other 
related respiratory dysfunction in later childhood, according to inconclusive evidence in this 
study and current published literature on this topic. Regardless of the true causal relation, 
however, the overall public health message concerning unnecessary antibiotic use shall remain 
unchanged. For children in particular, rational antibiotic prescribing is achievable
48–50
 and 
critical for minimizing unnecessary side effects at the individual level, healthcare expenditures 
for acute clinical consultation,
32
 and bacterial resistance at the population level. 
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APPENDIX A: SUPPLEMENTARY METHODOLOGICAL DETAIL, INTERRUPTED 
TIME SERIES ANALYSIS. 
 
1. We hypothesized that each interruption would have a gradual effect on the trend of antibiotic 
prescribing among infants over time. Therefore, we did not include parameters in our model 
that would measure discontinuity (i.e., changes in level) between adjacent segments.
159,201
  
2. Risk measurements corresponded to distinct cohorts of infants so that there was no risk 
carryover from the same infants being counted in multiple birth-weeks. Therefore our primary 
analysis did not account for serial autocorrelation of error terms. 
3. Overall annual risks were obtained by taking the mean of week-level predicted risks from the 
model presented in Figure 3.1 for the year of interest. 
4. Given the full segmented regression model, as defined previously,  
Rw = α + β0(time after 1 Jan 2004)w + β1(time after 1 May 2006)w + β2(time after 1 Jul 2007)w 
+ β3(time after 19 Jan 2010)w + β4(time after 1 Oct 2010)w + β5(sin(2πi/52)) + β6(cos(2πi/52)) 
variables for “time after” an interruption date were coded as 0 if the birth-week w occurred 
before the interruption, and as time (in weeks) since the interruption for birth-weeks occurring 
afterward. The coefficients of primary interest were:  
α, mean risk for births occurring immediately before January 2004;  
β0, baseline linear trend for risk before interruptions (1 January 2004 – 30 April 2006);  
β1, change in trend for risk after the interruption on 1 May 2006;  
β2, change in trend for risk after the interruption on 1 July 2007; 
β3, change in trend for risk after the interruption on 19 January 2010;  
β4, change in trend for risk after the interruption on 1 October 2010.  
  
APPENDIX B: OVERALL AND MEDICATION-SPECIFIC SUMMARIES OF RISK, RATE, AND BURDEN OVER TIME. 
Table B.1. Overall and selected medication-specific redeemed antibiotic prescriptions by year of birth in Denmark, 2004-2012 
(N=561,729).  
 
 
CI = confidence interval 
* Risk estimates for at least one redeemed antibiotic prescription for during infancy, using the complement of the Kaplan-Meier 
survival function which accounted for censoring at death or emigration. The sum of medication-specific risks exceeds overall risk 
because infants could be prescribed more than one medication in their first year.  
† Rate = no. of redeemed prescriptions per 100 infant-years of follow-up  
‡ Share of antibiotic rate = (no. of redeemed prescriptions) ÷ (total no. of redeemed prescriptions for all antibiotics) 
§ Population-level antibiotic drug burden = days supply per 10,000 infant-days of follow-up  
‖  Share of antibiotic burden = (days supplied) ÷ (total days supplied for all antibiotics)
8
3
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APPENDIX C: SENSITIVITY ANALYSES FOR INTERRUPTED TIME SERIES 
STUDY 
 
 We conducted four sensitivity analyses of the time series study to assess the effects of the 
number of interruptions we enumerated (analysis 1), how we controlled for seasonality (analyses 
2 and 3), and how we accounted for potential serial autocorrelation of error terms (analysis 4). 
Each sensitivity analysis is described in detail below, and results from these analyses are shown 
in Figure C.1 and Tables C.1 and C.2. 
 
Sensitivity analysis 1 
 In the first sensitivity analysis, we added an interruption on 1 January 2007 to relax prior 
assumptions about (1) the timing of the effects of the IRF bulletin and the PCV7 “catch-up” 
program and (2) the constancy over time of their effects on antibiotic use. In particular, the IRF 
bulletin was less current for children born after January 2007 since they were ≤3 months old 
when the bulletin was published. This sensitivity analysis introduced a new coefficient, β1a, 
which represented the change in trend after 1 January 2007. After this new interruption, we 
hypothesized that (1) the bulletin’s effect on the trend would be attenuated since children born 
after January 2007 would have been no more than 3 months old when the bulletin was published, 
before the vast majority of infants require consideration for their first antibiotic treatment, and 
(2) the “catch-up” program’s effect on the trend would be amplified since increasing numbers of 
children were enrolled over time. Given that we can only observe the mixture of these two 
effects, parsing the original second segment into two separate segments was intended to 
illuminate how their co-occurrence drove time-varying changes in antibiotic use. Figure C.1 
shows graphical results from the first sensitivity analysis. 
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Figure C.1.  Graphical results from the sensitivity analysis, which added a fifth interruption to 
the time series (denoted as 1a) to allow a 7-month lag of the first interruption. The graph shows 
segmented trend lines for the interrupted time series analysis of the risk of at least one redeemed 
prescription during the first year of life for any antibiotic (black), for amoxicillin (red), or for 
penicillin V (blue), by birth-week cohort among children born in Denmark during 2004-2012. 
Interruptions are denoted by downward arrows: (1) the near-coincident Institute for Rational 
Pharmacotherapy (IRF) bulletin and 7-valent pneumococcal conjugate vaccination (PCV7) 
“catch-up” enrollment schedule; (1a) the 7-month lag for the first interruption; (2) the standard 
program for PCV7 enrollment; (3) the nationwide transition from PCV7 to 13-valent 
pneumococcal conjugate vaccination (PCV13); and (4) the standard program for PCV13 
enrollment. Solid vertical lines crossing a segment indicate interruptions in the time series when 
potential changes in the trend for risk were assessed; dotted vertical lines indicate interruption 
1a, which allowed a 7-month lag for the first interruption. Segmented trend lines are adjusted for 
seasonality using a transformed cosine periodic function. For each segment, trend estimates are 
shown as the change in risk (%) per month. 
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Sensitivity analyses 2, 3, and 4 
 In the second and third sensitivity analyses, we controlled for seasonality using a vector 
of 51 birth-week indicator variables, using the first week of the year as the referent (sensitivity 
analysis 2), and using the cosine function in a two-stage weighted maximum likelihood 
estimation approach analogous to a weighted least squares approach
162
 (sensitivity analysis 3).  
 In the fourth sensitivity analysis, we conducted the primary analysis and prior three 
sensitivity analyses using autoregressive parameters to evaluate our assumption that there was no 
serial autocorrelation of error terms across birth-week cohorts. We assessed serial error 
autocorrelation between birth-week cohorts using Durbin-Watson test statistics.
202
 To account 
for error autocorrelation in sensitivity analyses, our model for the maximum likelihood estimator 
of the birth-week-specific risk included the vector of autoregressive parameters that allowed up 
to a 60-week lag; we used backward elimination to remove autoregressive parameters with a t-
statistic that was not significant based on an a priori type I error level of 0.05.
203
 
 
Summary of Tables C.1 and C.2 
 For each group of models, the Akaike Information Criterion (AIC) and log likelihood are 
shown. The AIC provides information on model performance relative to its efficiency, with more 
negative values indicating relative superiority, and the log likelihood provides information on the 
goodness of fit of the model. For each series of three models, the first row shows each parameter 
estimate based on a segmented linear regression model which controls for seasonality using a 
transformed cosine function (Approach A). The referent for α represents the risk (%), the 
referent for β0 represents the trend in risk (%) per month of calendar time, and the referents for 
β1, β2, β3, and β4 coefficients represent the change in trend at each interruption. 
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 The next two rows in each series show the difference in each parameter for models using 
Approach B or C compared to the referent model for the series. Plus (+) and minus (-) notation is 
used to show how estimates differ from the referent estimate for each series. For example, Model 
#1 estimated a referent risk of 40.1% (α), with an increase in the risk of 0.09% per month from 1 
January 2004 to 30 April 2006 (β0), and a change in the trend of -0.41% per month from 1 May 
2006 to 1 July 2007 (β1). For that series, Approach B (Model #2) differed from Approach A 
(Model #1) by -1.15% with respect to α, -0.003% with respect to β0, and +0.004% (shown as 
0.00) with respect to β1.  
 Models used in the primary analysis are shaded in gray, and graphical results for these 
models are shown in Figure 3.4 in the main text. The first sensitivity analysis can be reviewed in 
tabular form by comparing Table C.1 (using four interruptions) to the Table C.2 (which adds 
interruption 1a), as a comparison between Model #1 and Model #19. The second sensitivity 
analysis can be reviewed by comparing Approach B to Approach A for any specific setting (e.g., 
Model #2 versus Model #1). The third sensitivity analysis can be reviewed by comparing 
Approach C to Approach A for any specific setting (e.g., Model #3 versus Model #1). The fourth 
sensitivity analysis can be reviewed by comparing the results from models that assume 
independent error terms to results from autoregressive models for any specific setting (e.g., 
Model #10 versus Model #1). Results in Tables C.1 and C.2 show that trend changes were robust 
to multiple specifications that we considered for the linear model.
  
Table C.1.  Model fit criteria and parameter estimates across 4-interruption segmented linear regression models for the risk of at least 
one redeemed antibiotic prescription among infants born in Denmark, 2004-2012 (N=561,729). Gray shading denotes models used in 
the primary analysis. 
 
 
 
AIC = Akaike Information Criterion; LL = log likelihood 
* Approach A: one-stage maximum likelihood estimation of the risk, controlling for seasonality using a transformed cosine function. 
† Approach B: one-stage maximum likelihood estimation of the risk, controlling for seasonality using a vector of 51 birth-week 
indicator variables. 
‡ Approach C: two-stage weighted maximum likelihood estimation of the risk, controlling for seasonality using a transformed cosine function. 
8
8
 
  
Table C.2.  Model fit criteria and parameter estimates across 5-interruption segmented linear regression models for the risk of at least 
one redeemed antibiotic prescription among infants born in Denmark, 2004-2012 (N=561,729). 
 
 
 
 
AIC = Akaike Information Criterion; LL = log likelihood 
* Approach A: one-stage maximum likelihood estimation of the risk, controlling for seasonality using a transformed cosine function. 
† Approach B: one-stage maximum likelihood estimation of the risk, controlling for seasonality using a vector of 51 birth-week indicator 
variables. 
‡ Approach C: two-stage weighted maximum likelihood estimation of the risk, controlling for seasonality using a transformed cosine function.  
8
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APPENDIX D: DATA SOURCES AND DATABASE CODES TO ASCERTAIN 
EXPOSURE, OUTCOME, AND COVARIATES  
 
Structure of listing for different variable types: 
 
1. Listing structure for variables which required a code to ascertain occurrence:  
 [Variable] 
 [Data source], [Code Type]:  [code 1], [code 2], etc. 
 
2. Listing structure for variables with multiple sub-definitions of drugs or conditions: 
 [Variable] 
[Variable sub-definition A] 
[Data source], [Code Type]:  [code 1], [code 2], etc. 
[Variable sub-definition B] 
[Data source], [Code Type]:  [code 1], [code 2], etc. 
 
3. Listing structure for variables ascertained from database without using additional codes: 
 [Variable] 
[Data source], “individual-level value ascertained directly” 
 
4. Listing structure for variables based on admissions to hospital departments: 
 [Variable] 
 [Data source] 
Hospital Department(s) 
[code A] [code 1], [code 2], etc. 
 
n.b.:  i.  Database codes were used if they matched code segments preceding ‘x’ or ‘.x’ below. 
 ii.  Diagnosis codes to inform covariate definition were for primary discharge diagnosis only. 
 iii. An asterisk (*) denotes that a variable was ascertained using multiple data sources listed. 
iv. Abbreviations: 
MBR Danish Medical Birth Registry 
CRS Danish Civil Registration System 
NPR Danish National Registry of Patients 
NHSPD Danish National Health Service Prescription Database 
ATC Anatomic Therapeutic Chemical code in the NHSPD 
ICD-8   International Classification of Diseases Eighth Revision; diagnosis 
codes only, 1977-1993, ascertained from the NPR 
ICD-10 (D)   Diagnosis codes, International Classification of Diseases Tenth 
Revision, 1994- , ascertained from the NPR 
ICD-10 (K)  Surgery codes, International Classification of Diseases Tenth 
Revision, 1996- , ascertained from the NPR 
ICD-10 (B)   Treatment codes, International Classification of Diseases Tenth 
Revision, 1999- , ascertained from the NPR 
v. For data on patient visits to clinical specialists, administrative codes for the hospital and 
department admitting a patient were obtained from NPR data based on codes in the 
Health Care Classification System
153–155
 (available at 
http://www.medinfo.dk/sks/brows.php and ftp://filer.sst.dk/filer/sks/data/skscomplete/).  
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Exposure variables – prescriptions redeemed for antibiotic medications 
 
 Antibiotics for systemic use 
NHSPD, ATC: J01x 
 
 Amoxicillin 
NHSPD, ATC: J01CA04 
 
 Penicillin V 
NHSPD, ATC: J01CE02 
 
Outcome variables – obstructive airway diseases 
 
 Prescriptions redeemed for medications to treat airway diseases  
Inhaled β2-adrenoreceptor agonists 
NHSPD, ATC: R03AC02, R03AC03, R03AC04, R03AC12, R03AC13 
Inhaled glucocorticoids 
NHSPD, ATC: R03BA01, R03BA02, R03BA05 
Leukotriene receptor antagonists  
NHSPD, ATC: R03DC03 
Inhaled fixed combinations of glucocorticoids and β2-adrenoreceptor agonists 
NHSPD, ATC: R03AK06, R03AK07 
 
 Child asthma diagnosis 
NPR, ICD-10 (D): J45.0x, J45.1x, J45.2x, J45.8x, J45.9x, J46.9x 
 
Covariates – Group 1 – demographic and family characteristics 
 
 Child sex  
MBR, individual-level value ascertained directly 
 
 Child birth order (mother's live births only)  
MBR, individual-level value ascertained directly 
 
 Child date of birth 
MBR, individual-level value ascertained directly 
 
 Maternal age at birth 
MBR, individual-level value ascertained directly 
 
 Maternal and paternal country of origin 
CRS, individual-level value ascertained directly 
 
 Child municipality and region of residence at birth  
CRS, individual-level value ascertained directly 
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 Population density of child municipality of residence at birth  
National census data taken on 1 January 2012 (available at http://www.StatBank.dk/bev22), 
individual-level value ascertained directly 
 
 Family history of redeeming antibiotic prescriptions 
NHSPD, ATC: J01x 
 
 Family history of redeeming prescriptions for obstructive airway disease 
NHSPD, ATC: R03AC02, R03AC03, R03AC04, R03AC12, R03AC13, R03BA01, R03BA02, 
R03BA05, R03DC03, R03AK06, R03AK07 
 
 Parental history of asthma diagnosis 
NPR, ICD-8: 493.x 
NPR, ICD-10 (D): J45.0x, J45.1x, J45.2x, J45.8x, J45.9x, J46.9x 
 
 Parental history of medical treatment for asthma or other respiratory disorders 
NPR, ICD-10 (B): GHR0x, GKCx, GFx, GHx 
 
 Parental history of inflammatory bowel disease  
NPR, ICD-8: 563.x, 569.04 
NPR, ICD-10 (D): K50.x, K51.x, K52.x 
 
 Child diagnosis of otitis media during first year of life 
NPR, ICD-10 (D): H65.x, H66.x, H67.x 
 
 Child diagnosis of conjunctivitis during first year of life 
NPR, ICD-10 (D): H10.x, H11.x 
 
 Child diagnosis of acute upper respiratory infection during first year of life 
NPR, ICD-10 (D): J00.x, J01.x, J02.x, J03.x, J04.x, J05.x, J06.x 
 
 Child diagnosis of virus-related lower respiratory diseases during first year of life 
Acute bronchitis 
NPR, ICD-10 (D): J20.x 
Acute bronchiolitis 
NPR, ICD-10 (D): J21.x 
Bronchitis, unspecified as to acute or chronic 
NPR, ICD-10 (D): J40.x 
Respiratory syncytial virus (RSV) pneumonia 
NPR, ICD-10 (D): J12.1x 
 
 Child diagnosis of pneumonia during first year of life (excluding RSV pneumonia) 
NPR, ICD-10 (D): J12.0x, J12.2x, J12.3x, J12.8x, J12.9x, J13.x, J14.x, J15.x, J16.x, J17.x, 
J18.x  
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 Child diagnosis of allergic rhinitis during first year of life 
NPR, ICD-10 (D): J30.x, J31.x 
 
 Child diagnosis of atopic dermatitis during first year of life 
NPR, ICD-10 (D): L20.x, L22.x, L23.x, L27.x 
 
Covariates – Group 2 – parent and child visits to clinical specialists 
 
 Admission to pulmonology specialists (for parents or child during first year of life) 
NPR 
Hospital Department(s) 
1301 32W 
1309 62 
1330 521, 52D, 52H, 52L, 52U, 52V 
1351 29 
1501 32, 04D 
1502 06E 
2000 211, 213, 21A, 21D, 21F 
1549 01 
2010 01 
2017 02 
3800 A0L, D0L, H03, H0L, N03, N0L, R03, R0L, V0L 
4202 37 
5000 60 
5001 05F 
5501 054, 05L, 45L 
6008 052, 054, 05L 
4271 01 
6620 11 
6630 04F, 30F 
6650 33N 
7005 05A 
7053 01 
7062 02 
7075 01 
7092 01 
8001 17, 27x 
 
 Admission to allergy specialists (for parents or child during first year of life) 
NPR  
Hospital Department(s) 
1301 01Dx, 13x 
1501 040x, 044x, 047x, 049x, 04Ex 
1549 01x 
2017 01x 
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3800 A0Wx, H0Wx, N0Wx 
2514 01x 
3026 01x 
3523 08x 
3528 01x 
4202 03x 
7053 01x 
7075 01x 
7092 01x 
8001 179x 
  
 Admission to ear-nose-throat specialists  (for parents or child during first year of life) 
NPR 
Hospital Department(s) 
1301 26x 
1309 43x 
1330 13x 
1501 15x 
2000 29x 
1349 01x 
1374 01x 
1376 01x 
1411 524x, 544x, 554x 
1416 01x 
1537 01x 
1567 017x 
2034 01x 
3800 E3x, Q0x, S6x, X2x 
4202 20x, 21x 
5000 30x 
5001 11x 
5501 083x, 08Hx, 08Nx 
6008 12x 
6018 01x 
6620 19x 
6630 08x 
6650 41x 
7005 12x 
7039 01x 
7052 01x 
7617 01x 
7618 01x 
8001 22x, 23x 
7603 08x, 108x 
8034 01x 
9001 024x 
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 Admission to pediatrician specialists (for child during first year of life) 
NPR 
Hospital Department(s) 
1301 32x, 23Bx 
1411 525x, 535x 
1330 164x, 60x 
1501 04Dx, 18x 
1502 17x 
1516 37x 
2000 10x 
1590 01x 
3800 B0x, H8x, N9x, V9x 
2514 01x 
3523 05x 
3528 01x 
3529 01x 
4202 074x, 25x 
5000 23x 
5001 13x 
5501 046x, 04Bx 
6007 11x 
6006 24x 
6620 24x 
6630 081x, 09x 
6650 24x 
7005 15x 
8001 25x 
8003 16x 
 
Covariates – Group 3 – characteristics of mother and pregnancy 
 
 Twin or multiple pregnancy 
MBR, individual-level value ascertained directly 
 
 Cesarean delivery for any prior birth* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O34.2x, O75.7x, Z35.8Ex 
 
 Number of prior miscarriages 
MBR, individual-level value ascertained directly 
 
 Parity 
MBR, individual-level value ascertained directly 
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 Maternal smoking during pregnancy* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): F17.x, P04.2x, T65.2x, Z35.8M18x, Z39.318x, Z58.7x, Z71.6x, Z72.0x, 
VRB0x 
NHSPD, ATC: N07BA01, N07BA02, N07BA03, N06AX12, N06AA10, C02AC01, N02CX02, 
S01EA04, A08AX01 
 
 Maternal pregravid weight 
MBR, individual-level value ascertained directly 
 
 Maternal pregravid body mass index 
MBR, individual-level value ascertained directly 
 
 Maternal prescription redemption for inhaled or oral corticosteroid during pregnancy 
NHSPD, ATC:  R03BA01, R03BA02, R03BA05, R03BA07, R03AK06, R03AK07, H02AB04, 
H02AB06, H02AB07, H02AB09 
 
 Maternal acid-suppressive drug use during child’s pregnancy 
NHSPD, ATC:  A02B.x 
 
 Maternal diagnosis of high-risk pregnancy supervision 
NPR, ICD-10 (D): Z35.x 
 
 Maternal diagnosis of venous complications or hemorrhoids 
NPR, ICD-10 (D): O22.x 
 
 Maternal diagnosis of chronic hypertension 
NPR, ICD-10 (D): I10.x 
 
 Maternal diagnosis of gestational diabetes 
NPR, ICD-10 (D): O24.4x 
 
 Maternal diagnosis of other (non-gestational) diabetes 
NPR, ICD-10 (D): O24.0x, O24.1x, O24.3x, O24.5x, O24.9x 
 
 Maternal diagnosis of other illness complicating birth* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O98.x 
 
 Maternal diagnosis of other pregnancy complications* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O26.6x, O35.9x, O36.0x, O36.1x 
 
 Maternal admission to general practitioner during pregnancy 
MBR, individual-level value ascertained directly 
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 Maternal admission to midwife during pregnancy 
MBR, individual-level value ascertained directly 
 
 Maternal admission to obstetrician-gynecologists or other specialists during pregnancy* 
MBR, individual-level value ascertained directly 
NPR 
Hospital Department(s) 
1301 52x 
1330 16x 
1502 04x 
1516 04x 
2000 25x 
3800 B9x, J3x, P6x, S2x, W9x 
4202 07x 
5001 04x 
5002 11x 
5003 07x 
5501 04x 
6007 04x 
6200 33x 
6650 29x 
7005 04x 
8001 08x 
8003 04x 
7603 10x 
9001 02x 
 
Covariates – Group 4 – characteristics at birth event 
 
 Child place of birth (home vs hospital) 
MBR, individual-level value ascertained directly 
 
 Child born in a university-affiliated hospital 
MBR, individual-level value ascertained directly 
 
 Premature rupture of fetal membranes* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O42.x 
 
 Preeclampsia 
NPR, ICD-10 (D): O14.x 
 
 Breech or other abnormal presentation* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O64.1x 
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 Placenta previa* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O44.x 
 
 Gestational age at birth 
MBR, individual-level value ascertained directly 
 
 Epidural analgesia during labor* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (B): ABZ00x 
 
 Any surgical induction during labor* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): MACx 
 
 Operative vaginal delivery (vacuum or forceps extraction)* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): MAEx, MAFx 
 
 Amnioinfusion during labor* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): MAC20x, MAC30x 
 
 Maternal birth injury* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D):  O70.0x, O70.1x, O70.2x, O70.3x 
 
 Episiotomy* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): TMD00x 
 
 Surgery to repair maternal birth injury* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): MBC.x 
 
 Cesarean delivery for this birth* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O82.x 
NPR, ICD-10 (K): MCA10x 
 
 Cesarean delivery for this birth, upon maternal request* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (K): ZYM00x 
 
 Planned cesarean delivery for this birth* 
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MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O82.0x  
NPR, ICD-10 (K): MCA10Bx 
 
 Emergency cesarean delivery for this birth* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O82.1x  
NPR, ICD-10 (K): MCA10Ax, MCA10Cx, MCA10Dx, MCA10Ex 
 
 Post-partum hemorrhage or bleeding* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O72.x 
 
 Fixed placenta or fetal membranes* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O73.x 
 
 Navel cord prolapse 
MBR, individual-level value ascertained directly 
 
 Test of scalp pH to assess fetal asphyxia* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (B):  MBA03x 
 
 Fetal asphyxia* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): O36.3x, O68.x 
 
 Apgar score 5 minutes post-partum 
MBR, individual-level value ascertained directly 
 
 Birth weight 
MBR, individual-level value ascertained directly 
 
 Birth length 
MBR, individual-level value ascertained directly 
 
 Placental weight 
MBR, individual-level value ascertained directly 
 
Covariates – Group 5 – characteristics of perinatal period 
 
 Mother’s length of hospital stay for birth 
MBR, individual-level value ascertained directly 
 
 Child’s length of hospital stay after birth 
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MBR, individual-level value ascertained directly 
 
 Child’s length of hospital stay in neonatal intensive care unit (NICU) 
MBR, individual-level value ascertained directly 
 
 Child, continuous positive airway pressure administered in NICU* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (B): GFC32x 
 
 Child, respiratory aid in NICU* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (B): GDA0x 
 
 Child diagnosis of sepsis during first month of life* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): P36.x 
 
 Child diagnosis of conditions originating in the perinatal period 
NPR, ICD-10 (D): P0x, P1x, P2x, P5x, P6x, P7x, P8x, P9x 
 
 Child diagnosis of congenital malformation during first year of life* 
MBR, individual-level value ascertained directly 
NPR, ICD-10 (D): Qx 
 
Description of geographic covariate data  
 
 Until 31 December 2006, Denmark was divided into 270 districts. On 1 January 2007, its 
government consolidated those districts into 98 municipalities, and allocated each municipality to one of 
five regions. To compare geographic data over the entire study period, we harmonized data according to 
the 98-municipality data structure, and used national census data taken on 1 January 2012 (available 
from Statistics Denmark, http://www.StatBank.dk/bev22) to assign each municipality a value for 
population density (number of residents per square kilometer).  
We assigned geographic location for municipality and region for the child’s birth (using data 
from the MBR) and their residence following birth (using the CRS). Home births were classified 
by the mother’s residence (using the CRS) on the child’s date of birth. For hospital births, we 
used a historical list of hospitals obtained from the Health Care Classification System
153–155
 
(http://www.medinfo.dk/sks/brows.php, ftp://filer.sst.dk/filer/sks/data/skscomplete/) and 
conducted online searches to identify and confirm each hospital’s municipality and region, and 
classified each hospital as university-affiliated or not. There were five hospital codes in the 
historical list that pertained to groups of neighbouring hospitals, and we assigned each of those 
codes to the most densely populated municipality included in that code’s coverage area. For 
example, Fredericia Hospital and Kolding Hospital were <30 km apart and were grouped 
together as #6007; because Fredericia Municipality’s population density was approximately 
twice that of Kolding Municipality, we assigned #6007 to Fredericia Municipality.  
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APPENDIX E: SUPPLEMENTAL METHODOLOGICAL DETAIL, PROPENSITY 
SCORE ANALYSIS 
 
Missing data  
 All eight covariates with missing data were continuous or discrete-numeric: parity (1.5% 
of values missing), maternal pregravid weight (5.1%) and BMI (5.9%), gestational age at birth 
(0.3%), Apgar score 5 minutes post-partum (0.9%), birth weight (0.6%), birth length (1.4%), and 
placental weight (2.8%).  
 
Bronchitis, bronchiolitis, and respiratory syncytial virus diagnosis during the first year of life 
 Unmasking bias or detection signal bias
114,117,118
 can arise when an exposure induces 
symptoms that lead to a search for disease and potential diagnosis of the outcome. This is similar 
to protopathic bias, which can arise when underlying preclinical symptoms of the outcome of 
interest affect the treatment of interest. The two biases are distinct from one another, however, 
because unmasking bias occurs based on the extent of searching to detect and diagnose an 
outcome related to symptoms which were observed following treatment (rather than before 
treatment as is the case with protopathic bias). In the context of antibiotics and asthma, this could 
occur if a patient infected with respiratory syncytial virus (RSV) were mistakenly treated with 
antibiotics for a suspected bacterial infection. If the viral infection proceeded to cause bronchitis, 
bronchiolitis or wheeze,
41
 then the antibiotic would likely be recognized as ineffective and the 
rule-out diagnosis of bacterial infection would likely be deemed untrue or insufficient. 
Regardless, the healthcare claims records would still reflect the occurrence of a redeemed 
antibiotic prescription. As wheeze symptoms may be persistent,
41
 the practitioner could 
subsequently prescribe treatment related to asthma; in such a scenario, the record of an antibiotic 
prescription would be an artefact of the practitioner’s differential diagnosis method rather than as 
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a cause of asthma. Although diagnosis of wheeze during infancy was exceedingly rare in this 
population (4 children out of 542,237), controlling for diagnosis of bronchitis, bronchiolitis, and 
other outcomes related to respiratory syncytial virus during infancy was carried out reduce 
potential unmasking bias and protopathic bias. 
 
Residual confounding in dose-response estimation 
 In the portion of the dose-response analysis that compares one redeemed antibiotic 
prescription versus none, there is more potential for residual confounding (e.g., by indication) 
because the unexposed group may have pronounced (unmeasured) differences from the exposed 
which bias data interpretation. For the other four discrete dose-response comparisons between 
subgroups of the exposed, such confounding is likely minimized.  
   
Heterogeneity of effects by age 
In the PS-based analyses to assess for heterogeneity of risk differences by age at first 
redeemed antibiotic prescription, for each month of age m={0, 1, 2, ..., 12}, we enumerated a 
cohort comprising infants who redeemed their first antibiotic prescription that week (the exposed 
group) or remained naïve to antibiotic prescription between birth and month m (unexposed). For 
each month separately, we used SMR weighting to balance covariate distributions across 
exposure groups and estimated the ATT risk difference for antibiotic exposure. Across the series 
of analyses by month of age, infants classified as exposed in month m did not contribute to risk 
difference estimates from month m+1 through 12. 
The apparent increase in standardized risk differences across the first 3-4 months of life 
may describe a weaker effect of very early antibiotic exposure on treated airway disease; 
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however, it may reveal exposure misclassification or unmeasured confounding in early life, 
despite our having restricted to children not admitted to neonatal intensive care. The optimal 
conditioning set of covariates is likely different for each age-specific exposure contrast; given 
that 91% of infants’ first redeemed antibiotic prescription occur between 4-12 months of age, 
characteristics measured during infancy may enhance confounding control for contrasts later in 
infancy. 
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APPENDIX F: SUPPLEMENTAL METHODOLOGICAL DETAIL, INSTRUMENTAL 
VARIABLE ANALYSES 
 
Defining the birth-season instrumental variable: the problem 
Figure F.1 shows the cumulative incidence functions for antibiotic exposure by age 
through the first year of life, stratified by birth-season. It illustrates the need to consider more 
than the strength of the instrument-exposure relation when selecting the optimal instrument.  
 
Figure F.1. Risk function for at least one redeemed antibiotic prescription, by age (in months) 
through the first year of life, stratified by season of birth, Denmark 2004-2012. 
 
Season of birth is associated with incidence of antibiotic exposure; however, in addition 
to being associated with a pointwise difference in risk at 12 months for example, the relation 
between season of birth and risk of antibiotic exposure varies with increasing age. This variation 
is shown in Figure F.1 by the interweaving risk functions for each season of birth, leading to 
inconsistent differences between seasons depending on the age at comparison. Given that 
age
36,168
 at first antibiotic exposure may be an important modifier of the association between 
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antibiotics and treated airway diseases, the effect of the birth-season instrument on age at first 
exposure could cause potential violation of the ‘exclusion restriction’ assumption for IV analysis. 
This is the condition that requires the instrument may only be associated with the outcome 
through the exposure; a violation would arise from the causal pathway: birth-season  age-at-
exposure  treated-airway-diseases. Additionally, violation of the ‘random assignment’ 
assumption could arise in the presence of an association between birth-season and age-at-
exposure if any non-causal (i.e., biasing) pathways exist between age-at-exposure and treated-
airway-diseases, which is likely. The directed acyclic graph in Figure F.2 shows the potential 
violations that arise when there is an association between the birth-season instrument and age.  
 
Figure F.2.  A simplified directed acyclic graph for the birth-season instrument context. 
 
 
In addition to increasing the potential for violation of IV assumptions, an association 
between the birth-season instrument and age at first antibiotic exposure would hinder meaningful 
interpretation of risk difference estimates from the IV analysis. Consider a binary instrument that 
may at first appear (from Figure F.1) to be the best available option because its association with 
risk of antibiotic exposure during infancy is the strongest at 12 months of age. This instrument 
would compare spring (i.e., March, April, May) with autumn (i.e., September, October, 
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November) births, and would be associated with a 12-month risk difference for antibiotic 
exposure, 44.8–34.3 = 10.5%. However, the exposure difference between spring and autumn 
births was inconsistent in sign and disproportionate in magnitude across ages (Table F.1).  
 
Table F.1. Antibiotic exposure by age (in months), comparing spring and autumn births, 
Denmark 2004-2012. 
 
 
Percent exposed (%) 
 Age (months) Spring Autumn Difference (%) 
3 2 3 -0.8 
6 7 12 -5.0 
9 23 22 1.6 
12 45 34 10.5 
 
If the instrument-exposure association is inconsistent with age (or during any time period 
when the effect of exposure on outcome occurrence is in question), interpretation may become 
complicated. For the purposes of illustration, let us assume the ‘reduced-form’ or ‘intention-to-
treat’ IV estimate for the risk difference at 5 years of age was 2%, using the spring/autumn 
instrument. (For every 100 infants who redeemed an antibiotic prescription during their first year 
of life, 2 more would have been treated for airway diseases by 5 years of age, compared to every 
100 infants who did not redeem an antibiotic prescription.) Using a simple sign test, our 
observation that spring births had 10.5% higher antibiotic exposure at 12 months would suggest 
that antibiotic exposure increased the risk for treated airway diseases (LATE ≈ 0.02 ÷ 0.105).  
On the other hand, if we only had data on – or only thought to observe – antibiotic 
exposure data at 6 months of age, our interpretation of the estimate would contradict the above. 
Recall from Table F.1 that spring birth was associated with lower antibiotic exposure at 6 months 
compared to autumn births (-5%). Observing the instrument-outcome association were positive 
(2%), we would deduce a negative association between antibiotic exposure and treated airway 
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diseases (LATE ≈ 0.02 ÷ (-0.05)). Especially given the hypothesis that younger infants have a 
less stable microbial structure than older infants
204
 and may therefore be more susceptible to 
adverse effects from disruptions of the microflora – it may be implausible to conclude that 
antibiotic exposure during the first six months decreased risk of treated airway diseases, but 
exposure during months 6-12 led to increased risk of treated airway diseases.  
 
Defining the birth-season instrumental variable: approach 
If a birth-season instrument could be identified such that the association between birth-
season and age were minimized (to the extent that it would be plausible to remove the 
corresponding arrow in Figure F.2), then violation of IV assumptions would be less probable, 
and interpretation more straightforward. To optimize the instrument, we selected birth-month 
contrasts that exhibited the largest difference
60
 in antibiotic exposure without being associated 
with age at first redeemed antibiotic prescription, thus reducing potential violation of 
assumptions, since age
36,168
 at first antibiotic exposure may modify the association between 
antibiotics and treated airway diseases. We therefore examined each birth-month’s cumulative 
incidence function for antibiotic exposure by age during the first year of life, in search of two 
contrastable season-based time periods with functions that did not cross and have conflicting 
difference measures across the age continuum. Figure F.3 (on following page) is similar to 
Figure F.1, but displays exposure functions stratified by the more granular classification of birth-
month, showing the continuous nature of the interaction between birth-season and age at first 
exposure. 
 
 
 
108 
 
Figure F.3. Risk function for at least one redeemed antibiotic prescription, by age (in months) 
through the first year of life, stratified by month of birth, Denmark 2004-2012. 
 
 
 
 We sought birth-season instruments that would lead to as little violation of assumptions 2 
and 3 as discussed above, while maintaining as much strength as possible for the instrument-
exposure association. For exposure at 12 months, we observed that the optimal instrument 
compared children born in March and April (index level of the instrument) with children born in 
December and January (referent). Grouping months together in each arm of the instrument led to 
the most optimal weak association between the instrument and age at first exposure, thus 
reducing potential for violating assumptions 2 and 3. As shown in Figure F.4 and Table F.2, 
antibiotic exposure in the first 6 months was similar for both levels of the instrument. From 7 
months of age onward, the instrument was associated with differences in exposure, resulting in a 
cumulative difference of 7.0%, among the largest of all candidate birth-month comparisons. 
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Figure F.4. 12-month risk function for at least one redeemed antibiotic prescription by age 
(in months), stratified by birth-season instrument level, Denmark 2004-2012. 
 
 
Table F.2. Antibiotic exposure by age (in months), comparing March/April and 
December/January births, Denmark 2004-2012. 
 
 
Percent exposed (%) 
 Age (months) Mar/Apr Dec/Jan Difference (%) 
3 2 3 -1.1 
6 6 8 -2.0 
9 22 17 4.5 
12 45 38 7.0 
 
 For antibiotic exposure at 9 months, we observed that the optimal instrument compared 
children born in July and August (index) with children born in December and January (referent). 
Exposure was similar across levels of the instrument until 5 months of age; from 5 to 9 months, 
the instrument was associated with differences in exposure, resulting in a cumulative difference 
of 9.3% (Figure F.5, Table F.3). 
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Figure F.5. 9-month risk function for at least one redeemed antibiotic prescription by age 
(in months), stratified by birth-season instrument level, Denmark 2004-2012. 
 
 
Table F.3. Antibiotic exposure by age (in months), comparing July/August and 
December/January births, Denmark 2004-2012. 
 
 
Percent exposed (%) 
 Age (months) Jul/Aug Dec/Jan Difference (%) 
3 2 3 -1.1 
6 11 8 2.4 
9 27 17 9.3 
 
For antibiotic exposure at 6 months, we observed that the optimal instrument compared 
children born in September (index) with children born in March (referent). Exposure was similar 
until 3 months of age; from 3 to 6 months, the instrument was associated with differences in 
exposure, resulting in a cumulative difference of 6.3% (Figure F.6). 
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Figure F.6. 6-month risk function for at least one redeemed antibiotic prescription by age 
(in months), stratified by birth-season instrument level, Denmark 2004-2012. 
 
 
 
Defining the calendar-time instrumental variable 
The directed acyclic graph in Figure F.7 (on following page) is an extension of Figure 
F.2, in that it shows how the calendar-time instrument relates to other variables in this setting. 
We observed that calendar time is only associated with age at first antibiotic exposure through 
the intermediate of birth-season. The concern regarding the relation between birth-season and 
age applies in the context of the calendar-time IV analysis if the calendar-time instrument were 
associated with birth-season, since it would open both causal and non-causal paths between 
instrument and outcome in addition to the (intended) causal path from instrument through 
exposure to outcome.  
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Figure F.7.  A simplified directed acyclic graph for the calendar-time instrument context. 
 
 
To minimize potential bias induced by the relation between calendar time and season of 
birth, we based our instrument on a comparison of birth cohorts that shared the same season of 
birth. Thus, we implemented restriction to realize conditional independence between calendar 
time and season of birth, as shown in Figure F.8.  
 
Figure F.8. A simplified directed acyclic graph for the context of the calendar-time 
instrument restricted to similar seasons of birth. 
 
 
Figure F.9 shows exposure data over time that contributed to the specification of the 
calendar-time instrument. 
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Figure F.9. Index and referent levels of the calendar-time instrument, shown as groups of 
birth-week-specific risks of at least one redeemed antibiotic prescription during 
the first year of life, Denmark, 2005-2007. 
 
 
Using 1 May 2006 as the cutpoint for the pre- versus post- definition of the calendar-time 
instrument, we defined the index level of the instrument as births occurring from 12 March 2006 
through 29 April 2006 (7 weeks). Based on the birth-season restriction and the restriction of the 
time between instrument levels to one year, we defined the referent level of the instrument as 
births occurring one year later. To strengthen the instrument while maintaining near complete 
overlap of seasons, we used 5 March 2007 through 22 April 2007 as the referent. We excluded 
all other birth-week cohorts from the calendar-time IV analysis. 
In a sensitivity analysis, we strengthened the association between instrument and 
exposure by trimming birth-week cohorts that weakened the association. For both levels, we 
trimmed 19-25 of March and 2-8 April; these were the two lowest internal risk values in the 
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index level of the instrument, and the two highest the following year for the referent level. 
Because these trimmed birth-week cohorts were internal to the time windows for each level, and 
because the differences between their risk estimates and the surrounding weeks can be 
considered due to random error, we used the sensitivity analysis to explore the potential impact 
of a stronger instrument on inference. 
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APPENDIX G: TABLES DESCRIBING SELECTED CHARACTERISTICS RELATED 
TO THE ‘ANY-VERSUS-NONE,’ ‘ANY-AMOXICILLIN,’ AND ‘FIRST-ANTIBIOTIC’ 
EXPOSURE CONTRASTS. 
 
Table G.1. Extended table describing selected characteristics of infants born in Denmark during 
2004-2012, by level of antibiotic exposure during the first year of life (‘any-versus-none’) in 
observed data and stabilized standardized morbidity ratio (SMR) weighted data; N=541,336. 
 
  Observed data   Weighted data 
 
Exposed Unexposed 
  
Unexposed 
 
 
n = 214,256 n = 327,080 
  
mw = 1.005 
   % % SMD   % SMD 
Male sex 55.8 48.2 0.15 
 
55.9 0.00 
Birth order (mother's live births only) 
  
0.17 
  
0.01 
First-born 39.4 47.7 
  
39.1 
 Second 41.1 34.8 
  
41.4 
 Third 14.8 13.4 
  
14.9 
 Fourth 3.5 3.0 
  
3.4 
 Fifth or higher 1.3 1.0 
  
1.2 
 Year of birth 
  
0.07 
  
0.01 
2004-2006 36.4 33.2 
  
36.8 
 2007-2009 33.8 34.2 
  
33.7 
 2010-2012 29.8 32.5 
  
29.5 
 Season of birth 
  
0.16 
  
0.01 
Winter (Dec, Jan, Feb) 23.5 23.3 
  
23.8 
 Spring (Mar, Apr, May) 28.5 22.8 
  
28.4 
 Summer (Jun, Jul, Aug) 26.6 26.9 
  
26.3 
 Autumn (Sep, Oct, Nov) 21.4 27.0 
  
21.4 
 Maternal age at birth, years (median, IQR) (30, 27-34) (31, 28-34) -0.10 
 
(30, 27-34) 0.00 
Region of residence at birth 
  
0.18 
  
0.00 
Capital Region 32.9 33.5 
  
32.7 
 Zealand Region 14.9 11.6 
  
14.9 
 Southern Region 22.9 18.9 
  
22.9 
 Central Region 19.8 26.0 
  
19.8 
 North Region 9.6 10.1 
  
9.7 
 Population density of municipality of 
residence at birth, residents per km2 (median, 
IQR) (161, 85-744) (177, 87-794) -0.08 
 
(161, 85-744) 0.00 
Age at first redeemed antibiotic prescription 
  
-- 
  
-- 
≤6 months 22.6 0.0 
  
0.0 
 7-9 months 34.2 0.0 
  
0.0 
 10-12 months 43.2 0.0 
  
0.0 
 Mother, no. antibiotic prescriptions during 
pregnancy* 
  
0.16 
  
0.00 
0 63.2 70.3 
  
63.3 
 1 22.2 19.5 
  
22.2 
 ≥2 14.6 10.3 
  
14.5 
 Mother, rate of antibiotic prescription†‡ 
  
0.28 
  
0.00 
0 15.8 22.3 
  
15.8 
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>0-0.5 34.8 40.8 
  
34.9 
 >0.5-1 27.2 23.4 
  
27.3 
 >1 22.2 13.5 
  
22.0 
 Father, rate of antibiotic prescription†‡ 
  
0.17 
  
0.00 
0 34.7 41.0 
  
34.7 
 >0-0.5 44.2 43.5 
  
44.2 
 >0.5-1 15.2 11.7 
  
15.1 
 >1 6.0 3.9 
  
6.0 
 Older siblings, combined rate of antibiotic 
prescription†‡ 
  
0.39 
  
0.01 
0 43.3 54.3 
  
42.9 
 >0-1 20.7 25.7 
  
20.8 
 >1-2 18.0 12.6 
  
18.2 
 >2 18.0 7.3 
  
18.1 
 Mother, history of any obstructive airway 
disease† 16.1 12.9 0.09 
 
16.0 0.00 
Father, history of any obstructive airway 
disease† 12.0 10.8 0.04 
 
12.0 0.00 
Any older sibling, history of any obstructive 
airway disease† 22.3 15.2 0.18 
 
22.5 -0.01 
Diagnosis of otitis media† 2.4 0.2 0.19 
 
2.2 0.00 
Diagnosis of bronchitis, bronchiolitis, RSV 
pneumonia† 5.1 2.0 0.16 
 
5.1 -0.01 
Infant, no. admissions to pediatrician† 
  
0.27 
  
0.01 
0 69.1 80.1 
  
69.0 
 1 16.6 12.7 
  
16.7 
  ≥2 14.3 7.2 
  
14.2 
 Maternal smoking during pregnancy* 
  
0.09 
  
0.01 
Did not smoke 84.5 87.5 
  
84.4 
 Smoking, amount unknown 0.3 0.3 
  
0.3 
 Stopped smoking in first trimester 2.1 2.0 
  
2.1 
 Stopped smoking after first trimester 0.5 0.4 
  
0.5 
 Smoking, ≤5 cigarettes/day 3.8 3.1 
  
3.8 
 Smoking, 6-10 cigarettes/day 4.8 3.7 
  
4.9 
 Smoking, 11-20 cigarettes/day 3.5 2.6 
  
3.5 
 Smoking, >20 cigarettes/day 0.5 0.4 
  
0.5 
 Mother, no. visits to GP during pregnancy* 
  
0.05 
  
0.00 
0 14.5 16.1 
  
14.6 
 1-2 17.9 18.0 
  
17.9 
 3-4 65.5 64.2 
  
65.4 
  ≥5 2.0 1.7 
  
2.0 
 Mother, no. visits to midwife during 
pregnancy* 
  
0.05 
  
0.01 
0 7.1 8.1 
  
7.0 
 1-2 3.4 3.7 
  
3.5 
 3-4 29.5 30.4 
  
29.6 
  ≥5 59.9 57.9 
  
59.8 
 Mother, no. visits to ob-gyn during 
pregnancy* 
  
0.10 
  
0.00 
0 21.4 24.4 
  
21.3 
 1-2 48.2 48.8 
  
48.2 
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3-4 20.5 18.8 
  
20.6 
  ≥5 10.0 8.0 
  
9.9 
 Gestational age at birth, weeks 
  
0.04 
  
0.01 
<37 6.2 6.6 
  
6.4 
 37-39.9 43.3 41.4 
  
43.3 
  ≥40 50.5 52.0 
  
50.3 
 Operative vaginal delivery 7.4 8.5 -0.04 
 
7.4 0.00 
Cesarean delivery for this birth 22.7 21.7 0.03 
 
22.8 0.00 
Cesarean delivery upon maternal request 3.2 2.6 0.04 
 
3.2 -0.01 
Emergency cesarean delivery 12.8 12.8 0.00   12.8 0.00 
 
SMD = standardized mean difference (mean difference divided by pooled standard error) 
mw = mean weight 
IQR = interquartile range 
RSV = respiratory syncytial virus 
GP = general practitioner 
ob-gyn = obstetrician-gynecology specialist 
* Ascertained during the 245 days preceding the child's date of birth.  
† Ascertained until the child's first birthday. 
‡ Rate = number of prescriptions ÷ person-years of follow-up until the child's first birthday; 
extreme rates of medication use were imputed with the 99.9th percentile value from their rate-
specific distribution.
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Table G.2. Selected characteristics of infants born in Denmark during 2004-2012, by level of 
antibiotic exposure during the first year of life comparing children with at least one redeemed 
amoxicillin prescription to children with at least one penicillin V prescription but none for 
amoxicillin (i.e., ‘any-amoxicillin’) in observed data and inverse-probability-of-treatment (IPT) 
weighted data; N=202,576. 
 
  Observed data   Weighted data 
 
Amoxicillin Referent 
  
Amoxicillin Referent 
 
 
n = 139,970 n = 62,606 
  
mw = 1.000 mw = 0.999 
 
  % % SMD   % % SMD 
Male sex 56.3 55.1 0.02 
 
55.9 55.7 0.00 
Birth order (mother's live births only) 
  
0.03 
   
0.00 
First-born 38.9 40.4 
  
39.5 39.7 
 
Second 41.6 40.0 
  
41.0 40.9 
 
Third 14.7 14.9 
  
14.8 14.7 
 
Fourth 3.5 3.5 
  
3.5 3.5 
 
Fifth or higher 1.3 1.3 
  
1.3 1.2 
 
Year of birth 
  
0.07 
   
0.01 
2004-2006 35.3 38.6 
  
36.2 36.1 
 
2007-2009 34.7 32.3 
  
34.1 34.3 
 
2010-2012 29.9 29.0 
  
29.7 29.6 
 
Season of birth 
  
0.03 
   
0.01 
Winter (Dec, Jan, Feb) 23.4 23.7 
  
23.4 23.7 
 
Spring (Mar, Apr, May) 28.9 27.9 
  
28.6 28.5 
 
Summer (Jun, Jul, Aug) 26.7 26.6 
  
26.7 26.4 
 
Autumn (Sep, Oct, Nov) 21.0 21.9 
  
21.3 21.4 
 
Maternal age at birth, years (median, IQR) (30, 27-34) (30, 27-34) -0.02 
 
(30, 27-34) (30, 27-34) 0.00 
Region of residence at birth 
  
0.27 
   
0.01 
Capital Region 32.9 32.6 
  
32.8 32.9 
 
Zealand Region 17.2 10.7 
  
15.2 15.1 
 
Southern Region 24.1 20.7 
  
22.9 22.8 
 
Central Region 16.9 25.2 
  
19.5 19.5 
 
North Region 8.9 10.9 
  
9.6 9.7 
 Population density of municipality of 
residence at birth, residents per km
2
 
(median, IQR) (161, 87-794) (153, 81-672) 0.10 
 
(161, 85-744) (161, 84-749) 0.00 
Age at first redeemed antibiotic 
prescription 
  
0.03 
   
0.01 
≤6 months 23.6 17.8 
  
21.8 21.1 
 
7-9 months 35.8 31.9 
  
34.5 35.0 
 
10-12 months 40.5 50.3 
  
43.7 43.9 
 Mother, no. antibiotic prescriptions during 
pregnancy* 
  
0.08 
   
0.00 
0 62.1 65.3 
  
63.1 63.0 
 
1 22.6 21.6 
  
22.3 22.3 
 
≥2 15.4 13.1 
  
14.7 14.7 
 
Mother, rate of antibiotic prescription†‡ 
  
0.13 
   
0.00 
0 14.8 17.8 
  
15.7 15.7 
 
>0-0.5 33.9 36.5 
  
34.8 34.8 
 
>0.5-1 27.7 26.2 
  
27.3 27.3 
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>1 23.6 19.5 
  
22.3 22.2 
 
Father, rate of antibiotic prescription†‡ 
  
0.08 
   
0.00 
0 33.6 37.1 
  
34.6 34.7 
 
>0-0.5 44.6 43.4 
  
44.2 44.1 
 
>0.5-1 15.6 14.1 
  
15.2 15.2 
 
>1 6.3 5.4 
  
6.0 6.0 
 Older siblings, combined rate of antibiotic 
prescription†‡ 
  
0.17 
   
0.01 
0 42.5 44.7 
  
43.3 43.5 
 
>0-1 19.3 23.4 
  
20.6 20.6 
 
>1-2 18.2 17.7 
  
18.0 18.0 
 
>2 20.0 14.2 
  
18.1 17.9 
 Mother, history of any obstructive airway 
disease† 16.5 15.0 0.04 
 
16.0 15.9 0.00 
Father, history of any obstructive airway 
disease† 12.3 11.6 0.02 
 
12.1 12.1 0.00 
Any older sibling, history of any 
obstructive airway disease† 23.0 21.0 0.05 
 
22.3 22.3 0.00 
Diagnosis of otitis media† 3.0 1.3 0.12 
 
2.4 2.3 0.00 
Diagnosis of bronchitis, bronchiolitis, 
RSV pneumonia† 5.3 4.4 0.04 
 
5.0 5.0 0.00 
Infant, no. admissions to pediatrician† 
  
0.12 
   
0.00 
0 67.8 72.7 
  
69.4 69.4 
 
1 17.0 15.9 
  
16.6 16.7 
 
 ≥2 15.2 11.4 
  
14.0 13.9 
 Maternal smoking during pregnancy* 
  
0.02 
   
0.00 
Did not smoke 84.3 84.6 
  
84.4 84.5 
 Smoking, amount unknown 0.3 0.3 
  
0.3 0.3 
 Stopped smoking in first trimester 2.0 2.2 
  
2.1 2.1 
 Stopped smoking after first trimester 0.5 0.5 
  
0.5 0.5 
 Smoking, ≤5 cigarettes/day 3.9 3.8 
  
3.8 3.8 
 Smoking, 6-10 cigarettes/day 4.9 4.7 
  
4.8 4.8 
 Smoking, 11-20 cigarettes/day 3.6 3.4 
  
3.5 3.5 
 Smoking, >20 cigarettes/day 0.5 0.5 
  
0.5 0.5 
 Mother, no. visits to GP during 
pregnancy* 
  
0.07 
   
0.00 
0 13.7 16.1 
  
14.6 14.7 
 
1-2 18.2 17.1 
  
17.9 17.9 
 
3-4 66.0 64.7 
  
65.5 65.4 
 
 ≥5 2.0 2.2 
  
2.0 2.0 
 Mother, no. visits to midwife during 
pregnancy* 
  
0.05 
   
0.00 
0 6.7 7.7 
  
7.1 7.1 
 
1-2 3.4 3.4 
  
3.4 3.4 
 
3-4 29.2 30.4 
  
29.6 29.6 
 
 ≥5 60.7 58.5 
  
60.0 59.8 
 Mother, no. visits to ob-gyn during 
pregnancy* 
  
0.08 
   
0.00 
0 20.4 23.1 
  
21.3 21.3 
 
1-2 48.0 48.5 
  
48.1 48.2 
 
3-4 21.1 19.4 
  
20.6 20.5 
 
 ≥5 10.5 9.1 
  
10.0 10.0 
 
Gestational age at birth, weeks 
  
0.02 
   
0.00 
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<37 6.2 6.2 
  
6.2 6.3 
 
37-39.9 43.6 42.8 
  
43.3 43.2 
 
 ≥40 50.3 51.1 
  
50.6 50.6 
 
Operative vaginal delivery 
7.3 7.6 -0.01 
 
7.4 7.5 0.00 
Cesarean delivery for this birth 23.0 22.0 0.02 
 
22.7 22.7 0.00 
Cesarean delivery upon maternal request 3.3 2.9 0.02 
 
3.2 3.2 0.00 
Emergency cesarean delivery 12.9 12.5 0.01   12.8 12.9 0.00 
 
SMD = standardized mean difference (mean difference divided by pooled standard error) 
mw = mean weight 
IQR = interquartile range 
RSV = respiratory syncytial virus 
GP = general practitioner 
ob-gyn = obstetrician-gynecology specialist 
* Ascertained during the 245 days preceding the child's date of birth.  
† Ascertained until the child's first birthday. 
‡ Rate = number of prescriptions ÷ person-years of follow-up until the child's first birthday; 
extreme rates of medication use were imputed with the 99.9th percentile value from their rate-
specific distribution.
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Table G.3. Selected characteristics of infants born in Denmark during 2004-2012, by level of 
antibiotic exposure during the first year of life comparing children whose first redeemed 
antibiotic prescription was for amoxicillin versus penicillin V (i.e., ‘first-antibiotic’) in observed 
data and inverse-probability-of-treatment (IPT) weighted data; N=198,207. 
 
  Observed data   Weighted data 
 
Amoxicillin Penicillin V 
  
Amoxicillin Penicillin V 
 
 
n = 113,652 n = 84,555 
  
mw = 0.999 mw = 1.002 
 
  % % SMD   % % SMD 
Male sex 55.6 56.1 -0.01 
 
55.8 55.8 0.00 
Birth order (mother's live births only) 
  
0.01 
   
0.00 
First-born 39.6 39.4 
  
39.6 39.6 
 
Second 41.1 41.1 
  
41.0 41.0 
 
Third 14.6 14.9 
  
14.7 14.7 
 
Fourth 3.4 3.5 
  
3.5 3.5 
 
Fifth or higher 1.3 1.2 
  
1.2 1.2 
 
Year of birth 
  
0.09 
   
0.00 
2004-2006 34.3 38.6 
  
35.9 35.8 
 
2007-2009 35.2 32.5 
  
34.2 34.3 
 
2010-2012 30.5 28.9 
  
29.9 29.8 
 
Season of birth 
  
0.01 
   
0.00 
Winter (Dec, Jan, Feb) 23.3 23.7 
  
23.4 23.5 
 
Spring (Mar, Apr, May) 28.7 28.5 
  
28.6 28.6 
 
Summer (Jun, Jul, Aug) 26.6 26.7 
  
26.7 26.6 
 
Autumn (Sep, Oct, Nov) 21.4 21.1 
  
21.4 21.3 
 
Maternal age at birth, years (median, IQR) (30, 27-34) (30, 27-34) -0.01 
 
(30, 27-34) (30, 27-34) 0.00 
Region of residence at birth 
  
0.25 
   
0.00 
Capital Region 32.8 32.9 
  
32.7 32.7 
 
Zealand Region 18.0 11.6 
  
15.3 15.3 
 
Southern Region 24.2 21.1 
  
22.8 22.8 
 
Central Region 16.4 23.7 
  
19.5 19.5 
 
North Region 8.7 10.7 
  
9.6 9.6 
 Population density of municipality of 
residence at birth, residents per km
2
 
(median, IQR) (161, 87-797) (161, 84-672) 0.12 
 
(161, 87-744) (161, 84-749) 0.00 
Age at first redeemed antibiotic 
prescription 
  
0.03 
   
0.00 
≤6 months 21.5 20.1 
  
21.0 20.6 
 
7-9 months 35.0 34.5 
  
34.6 35.1 
 
10-12 months 43.5 45.5 
  
44.4 44.4 
 Mother, no. antibiotic prescriptions during 
pregnancy* 
  
0.04 
   
0.00 
0 62.5 64.0 
  
63.1 63.0 
 
1 22.5 22.0 
  
22.3 22.3 
 
≥2 15.1 14.0 
  
14.7 14.7 
 
Mother, rate of antibiotic prescription†‡ 
  
0.06 
   
0.00 
0 15.0 16.8 
  
15.7 15.7 
 
>0-0.5 34.5 35.4 
  
34.9 34.9 
 
>0.5-1 27.7 26.6 
  
27.3 27.3 
 
>1 22.8 21.2 
  
22.2 22.2 
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Father, rate of antibiotic prescription†‡ 
  
0.05 
   
0.00 
0 33.7 36.1 
  
34.6 34.7 
 
>0-0.5 44.8 43.5 
  
44.3 44.2 
 
>0.5-1 15.4 14.7 
  
15.1 15.1 
 
>1 6.2 5.7 
  
6.0 5.9 
 Older siblings, combined rate of antibiotic 
prescription†‡ 
  
0.07 
   
0.00 
0 43.3 43.4 
  
43.4 43.5 
 
>0-1 19.8 21.9 
  
20.6 20.6 
 
>1-2 17.9 18.0 
  
18.0 18.0 
 
>2 19.0 16.7 
  
18.0 18.0 
 Mother, history of any obstructive airway 
disease† 16.2 15.8 0.01 
 
16.0 16.0 0.00 
Father, history of any obstructive airway 
disease† 12.2 11.8 0.01 
 
12.0 12.0 0.00 
Any older sibling, history of any 
obstructive airway disease† 22.2 22.2 0.00 
 
22.2 22.2 0.00 
Diagnosis of otitis media† 2.7 2.2 0.03 
 
2.5 2.5 0.00 
Diagnosis of bronchitis, bronchiolitis, 
RSV pneumonia† 4.9 5.0 0.00 
 
5.0 5.0 0.00 
Infant, no. admissions to pediatrician† 
  
0.04 
   
0.00 
0 69.0 70.5 
  
69.6 69.5 
 
1 16.7 16.5 
  
16.6 16.6 
 
 ≥2 14.3 13.0 
  
13.8 13.8 
 Maternal smoking during pregnancy* 
  
0.01 
   
0.00 
Did not smoke 84.5 84.5 
  
84.5 84.5 
 Smoking, amount unknown 0.3 0.3 
  
0.3 0.3 
 Stopped smoking in first trimester 2.0 2.1 
  
2.1 2.1 
 Stopped smoking after first trimester 0.5 0.5 
  
0.5 0.5 
 Smoking, ≤5 cigarettes/day 3.8 3.9 
  
3.8 3.8 
 Smoking, 6-10 cigarettes/day 4.8 4.8 
  
4.8 4.8 
 Smoking, 11-20 cigarettes/day 3.5 3.4 
  
3.5 3.5 
 Smoking, >20 cigarettes/day 0.5 0.5 
  
0.5 0.5 
 Mother, no. visits to GP during 
pregnancy* 
  
0.07 
   
0.00 
0 13.5 15.9 
  
14.6 14.7 
 
1-2 18.4 17.0 
  
17.9 17.9 
 
3-4 66.1 64.9 
  
65.5 65.4 
 
 ≥5 2.0 2.2 
  
2.0 2.0 
 Mother, no. visits to midwife during 
pregnancy* 
  
0.05 
   
0.00 
0 6.7 7.6 
  
7.1 7.1 
 
1-2 3.3 3.5 
  
3.4 3.4 
 
3-4 29.1 30.2 
  
29.5 29.5 
 
 ≥5 60.9 58.8 
  
59.9 59.9 
 Mother, no. visits to ob-gyn during 
pregnancy* 
  
0.06 
   
0.00 
0 20.5 22.6 
  
21.4 21.3 
 
1-2 48.1 48.1 
  
48.0 48.0 
 
3-4 21.1 19.7 
  
20.6 20.6 
 
 ≥5 10.3 9.6 
  
10.0 10.0 
 
Gestational age at birth, weeks 
  
0.01 
   
0.00 
<37 6.2 6.1 
  
6.2 6.2 
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37-39.9 43.3 43.1 
  
43.2 43.2 
 
 ≥40 50.4 50.8 
  
50.6 50.6 
 
Operative vaginal delivery 
7.3 7.6 -0.01 
 
7.4 7.5 0.00 
Cesarean delivery for this birth 22.9 22.4 0.01 
 
22.7 22.7 0.00 
Cesarean delivery upon maternal request 3.2 3.1 0.01 
 
3.2 3.2 0.00 
Emergency cesarean delivery 12.9 12.6 0.01   12.8 12.8 0.00 
 
SMD = standardized mean difference (mean difference divided by pooled standard error) 
mw = mean weight 
IQR = interquartile range 
RSV = respiratory syncytial virus 
GP = general practitioner 
ob-gyn = obstetrician-gynecology specialist 
* Ascertained during the 245 days preceding the child's date of birth.  
† Ascertained until the child's first birthday. 
‡ Rate = number of prescriptions ÷ person-years of follow-up until the child's first birthday; 
extreme rates of medication use were imputed with the 99.9th percentile value from their rate-
specific distribution.
  
APPENDIX H: SENSITIVITY ANALYSIS OF RISK DIFFERENCE HETEROGENEITY BY AGE AT FIRST 
ANTIBIOTIC EXPOSURE, OMITTING CONTROL OF COVARIATES MEASURED DURING INFANCY.  
 
Figure H.1, below, shows higher risk differences and a more pronounced decreasing trend in the risk difference from 4-10 months of 
age, compared to results from the primary analysis. 
 
Figure H.1. Risk difference heterogeneity by age at first redeemed antibiotic prescription for the relation between antibiotic exposure 
and risk of treated airway diseases among children born in Denmark, 2004-2012, who were never admitted to neonatal intensive care.  
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APPENDIX I: BIAS POTENTIAL AND IMPRECISE ESTIMATION OF THE LOCAL AVERAGE TREATMENT EFFECT 
IN INSTRUMENTAL VARIABLE ANALYSES 
 
Table I.1. Summary measures of covariate imbalance between levels of the instrument in observed and weighted data based on the 
average standardized absolute mean difference (SAMD) and the average local average treatment effect (LATE) bias. 
  Observed data   Weighted data 
 Instrumental variable Average SAMD Average LATE bias*   Average SAMD Average LATE bias* 
Birth-season, 12 months† 0.02 0.24 
 
0.001 0.02 
Birth-season, 9 months‡ 0.02 0.18 
 
0.001 0.01 
Birth-season, 6 months§ 0.02 0.25 
 
0.002 0.03 
Calendar-time, primary‖ 0.03 0.70 
 
0.003 0.07 
Calendar-time, enhanced¶ 0.03 0.54   0.003 0.05 
SAMD = standardized absolute mean difference (absolute value of the quotient for the mean difference divided by the pooled standard 
error) 
LATE = local average treatment effect 
* Average LATE bias is equal to the average SAMD scaled by the instrument’s strength (average SAMD divided by compliance 
proportion)  
† Instrument regarding exposure differences at 12 months, comparing children born in March and April versus December and January 
‡ Instrument regarding exposure differences at 9 months, comparing children born in July and August versus December and January 
§ Instrument regarding exposure differences at 6 months, comparing children born in September versus March 
‖  Instrument regarding exposure differences at 12 months, comparing children born during 12 March-29 April 2006 versus 5 March-
22 April 2007 
¶  Instrument regarding exposure differences at 12 months, comparing children born during (12/3/2006-18/3/2006, 26/3/2006-
1/4/2006, 9/4/2006-29/4/2006) versus (5/3/2007-18/3/2007, 26/3/2007-1/4/2007, 9/4/2007-22/4/2007)
1
2
5
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APPENDIX J: RELATION BETWEEN TREATED AIRWAY DISEASES AND ASTHMA 
IN CHILDREN 
 
In our study, children were defined as having treated airway diseases if they redeemed at 
least one prescription for at least two (of the three) classes of outcome-related drugs. We grouped 
these prescriptions into three drug classes: (1) inhaled β2-adrenoreceptor agonists; (2) inhaled 
glucocorticoids; and (3) leukotriene antagonists.  
To illustrate the relation between treated airway diseases before age 5 and the occurrence 
of asthma in later childhood in Denmark, we compared our study outcomes with asthma status at 
7 years of age. We conducted this comparison within the subcohort of children in Denmark who 
had available data through their seventh birthday, and ascertained asthma status using data 
between their fifth and seventh birthday. Three comparison definitions were used: (1) the same 
criteria as treated airway diseases – at least one redeemed prescription for at least two classes of 
anti-asthma medications; (2) at least one discharge diagnosis code for asthma in the Danish 
National Registry of Patients (NPR), following a hospitalization, outpatient visit, or emergency 
department visit, and using the International Classification of Diseases Tenth Revision (ICD-10); 
(3) satisfaction of criteria in definitions 1 and 2. In database studies of childhood asthma, similar 
definitions to these have frequently been implemented.
5,6,79,116,151,205–208
  
To compare outcome classification by age and criteria, or each comparison using the 
definitions of 7-year asthma status as a series of pseudo-gold standards,
209
 we calculated a kappa 
coefficient,
210,211
 sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV), with 99% confidence intervals (CIs).  
Figure J.1 shows the relation between these outcomes at different ages in childhood. The 
absolute risk of being diagnosed with asthma between age 5 and 7 years was low (1.4%), but the 
proportion of children who received and redeemed prescriptions to treat airway diseases at those 
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ages was higher (4.4%). Among children diagnosed with asthma between age 5 and 7, 37% were 
treated for airway diseases by age 3, 53% were treated by age 4, and 65% were treated by age 5. 
Compared definitions of asthma based on prescriptions only or prescriptions and an observed 
diagnosis, sensitivity of the treated airway disease outcomes decreased by approximately 10% 
when asthma was defined based on an observed diagnosis only. Regarding specificity, among 
children who were not diagnosed with asthma between age 5 and 7, 94% were not treated by age 
3, 91% were not treated by age 4, and 90% were not treated by age 5. The PPV was consistent at 
30% for treated airway diseases at ages 3, 4, and 5 compared to age 7, but ranged 6-9% when the 
pseudo-gold standard incorporated an observed diagnosis to define asthma by age 7.  
(Figure J.1 on following page.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure J.1. Comparison between treated airway diseases before age 5 and three classifications of asthma at age 7 among children 
born in Denmark. The pseudo-gold standard in the left column was based on births from 2004-2008 since it relied 
solely on prescribing data which we obtained through 2015. The right two columns were based on births from 2004-
2005, since diagnosis data were not available after 2012.  
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APPENDIX K: INDIVIDUAL-LEVEL CHARACTERISTICS OF TREATED AIRWAY 
DISEASES OVER TIME 
 
To examine the stability in outcome classification in more granular time periods from 
year to year, we assessed agreement of treated airway diseases across discrete years of age from 
2 to 5. The tables below show trajectories of ‘current’ treated airway diseases status across 
distinct follow-up periods by age (in years) up to age 5. As in the primary analysis, treated 
airway diseases was defined as redeeming at least one prescription from at least two classes of 
drugs for obstructive airway diseases. To be classified with the outcome at a specific age, both 
redemptions had to occur within that year of age. 
Table K.1. ‘Current’ treated airway diseases (Yes/No) in each period for children observed 
for one year only, through 3rd birthday (n=58,176 births occurring in 2012)  
 
Age 2-3 Age 3-4 Age 4-5 % at age 3 
No -- -- 94.4 
Yes -- -- 5.6 
 
Table K.2. ‘Current’ treated airway diseases (Yes/No) in each period for children observed 
for two years only, through 4th birthday (n=58,696 births occurring in 2011)  
 
Age 2-3 Age 3-4 Age 4-5 % at age 3 % at age 4 
No No -- 
94.4 
92.4 
No Yes -- 2.0 
Yes No -- 
5.6 
2.9 
Yes Yes -- 2.7 
     
Table K.3. ‘Current’ treated airway diseases (Yes/No) in each period for children observed 
for three years, through 5th birthday (n=438,466 births occurring 2004-2010) 
   
Age 2-3 Age 3-4 Age 4-5 % at age 3 % at age 4 % at age 5 
No No No 
93.4 
91.4 
90.4 
No No Yes 1.1 
No Yes No 
2.0 
1.3 
No Yes Yes 0.7 
Yes No No 
6.6 
3.5 
3.0 
Yes No Yes 0.6 
Yes Yes No 
3.1 
1.4 
Yes Yes Yes 1.6 
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Using data from Tables K.2 and K.3, we calculated sensitivity and positive predictive 
value (PPV) for each comparison, and report them below. Calculations comparing age 3 versus 4 
are based on children born during 2004-2011, and calculations comparing age 3 versus 4 or 3 
versus 5 are based on children born during 2004-2010. 
Table K.4. Sensitivity and positive predictive value for ‘current’ treated airway diseases 
outcome status, comparing age 3 versus 4, age 4 versus 5, and age 3 versus 5. 
  
  Age 3 versus 4 Age 4 versus 5 Age 3 versus 5 
Sensitivity 0.60 0.59 0.56 
PPV 0.46 0.46 0.33 
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